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ABSTRACT
Monitoring the time course of drug in the skin is critical for determining the frequency
and dose of drug administration from safety and efficacy perspectives. Intermittent blood
sampling is used as a surrogate for approximating concentration of drugs in the tissues, which
leads to blood loss and discomfort to patients. A novel noninvasive technique called
“Electroporation and transcutaneous sampling” (ETS) was developed for estimating the drug
concentration in the skin extracellular fluid. The application of ETS technique in studying
dermatokinetics of cephalexin, ciprofloxacin, and 8-methoxypsoralen was investigated. The
results demonstrated the ability of ETS technique in dermatokinetic studies of drugs with
different physicochemical properties. ETS technique was also found to be a promising method
for noninvasive estimation of blood glucose levels.
Two novel techniques were developed for enhancing the transdermal delivery of drugs.
“ChilDrive”, a technique of combining regional cutaneous hypothermia with iontophoresis was
used for enhancing the bioavailability of transdermally administered drug in the deeper
musculoskeletal tissue like synovial fluid. The bioavailability of drugs in the synovial fluid of
knee joint was enhanced by ~6-12-fold and ~2-4-fold by ChilDrive when compared to passive
and iontophoretic transdermal drug delivery.
Magnetophoresis, a technique of enhancing transdermal drug delivery by application of
magnetic field was developed. The mechanistic studies demonstrated that transdermal
magnetophoresis of drugs was due to contribution of multiple factors such as magnetorepulsion,
magnetohydrokinesis and magnetically enhanced partition coefficient. Magnetophoretic patch
ii

system was designed and pharmacokinetic studies were performed. Magnetophoresis resulted in
higher dermal bioavailability of drugs compared to passive transdermal drug delivery. It was also
found from the in vitro studies that combination of chemical enhancers would further enhance
the efficiency of magnetophoretically mediated drug delivery enhancement.
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CHAPTER-1
INTRODUCTION

1.1. Skin
Skin is the outermost organ of the body which acts as a barrier protecting the body from
physical, chemical or microbial attacks, ultraviolet radiation, acts as thermostat in maintaining
body temperature and prevents water loss from the body. Skin comprises of two distinct regions;
the epidermis and dermis which rests on the subcutaneous tissue (Figure 1-1) (1, 2).

Stratum Corneum
Epidermis
Dermis
Subcutaneous tissue
Musculoskeletal tissue

Figure 1-1. Structure of skin
1.1.1. Epidermis
Epidermis is the outermost avascular layer with a thickness of ~0.075 to 0.15 mm. The
epidermal layer consists of 95% keratinocytes and the remaining 5% is composed of
melanocytes, langerhans cells and merkel cells. The epidermal region is further subdivided into
various

layers

like

stratum

corneum,
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stratum

granulosum,

stratum

spinosum, and stratum basale. The outermost layer of epidermis, stratum corneum (10-20 µm) is
the main barrier that prevents in and out entry of substances. The stratum corneum or horny layer
represents a brick and mortar model with the dead, keratinized cells embedded in a mortar of
lipid bilayers. It consists of 75-80% of protein which is mainly keratin and 5-15% of lipid. The
major contents of lipid domain include ceramides, fatty acids, cholesterol, and sterol/wax esters.
Water also plays an important role along with keratinocytes and lipid layers in maintaining the
barrier integrity of stratum corneum. The stratum granulosum, spinosum and basale constitute
the viable epidermis which is present below the stratum corneum. Keratinocytes, melanocytes,
langerhans cells and merkel cells constitute the viable epidermis (3-6).
1.1.2. Dermis
The layer of skin just below the viable epidermis is the dermis which constitutes the bulk
of skin and made of fibrous and elastic tissue. The dermis has a thickness of ~2 to 4 mm and
consists of numerous structures like blood vessels, lymphatic vessels, nerve endings, hair,
sebaceous glands, and sweat glands. The dermal region has extensive capillary network which
connects to systemic circulation with branching from the arterioles and venules. The lymphatic
vessels aid in the drainage of particulate and liquid matter from the dermis. The dermis also has
scattered fibroblasts, macrophages, leucocytes, and mast cells. One square centimeter of skin is
associated with about three blood vessels, 360 cm of nerves, 10 hair follicles, 15 sebaceous
glands, and sweat glands (7, 8).
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1.2. Transcutaneous sampling of drugs
In general, when the infection is present in the central pharmacokinetic compartment, the
activity of the drug is determined by the unbound drug concentration in the plasma. But, if the
infection is in the peripheral tissue like skin, it is the time course of unbound drug concentration
in the skin extracellular fluid (ECF) that is critical for successful drug therapy. ECF can be
considered as a liquid compartment in the close vicinity of cells in which drugs enter. In such
cases, monitoring drug levels in the plasma may not represent the actual levels in the affected
peripheral tissue. Moreover, the phlebotomical procedures are associated with blood loss and
discomfort in patients. Therefore, the time course of drugs in the affected tissue should be
monitored for determining the frequency and dose of drug administration from the safety and
efficacy perspectives (9-11).
1.2.1. Different techniques of sampling drugs from the dermal ECF
Conventional techniques of drug sampling from the dermal ECF include skin blister fluid
sampling and skin biopsy sampling. However, these techniques are invasive in nature and also
have a limitation with the number of samples that can be collected (12-16).
Microdialysis is a minimally invasive technique which is widely used for sampling of unbound
drug from the tissue extracellular fluid. To carryout cutaneous microdialysis a small probe
constructed with semipermeable membrane is inserted in the dermis and the principle involved is
that the physiological solution pumped through the probe is in equilibrium with the molecules
diffusing in the immediate surroundings (17). Microdialysis has been successfully employed for
the estimation of drugs like diclofenac, 5-fluorouracil, ibuprofen, propranolol, and nicotine in the
skin extracellular fluid (18-22). Microdialysis technique has certain limitations with
implementation in therapeutic drug monitoring. The drug recovery by microdialysis is affected
3

by various physicochemical and physiological factors and the major concern is the possibility of
damage to the skin microvasculature due to probe insertion leading to local ischemia and
effecting tissue metabolism (17, 23).
Reverse iontophoresis had been studied for transcutaneous sampling of caffeine, theophylline,
valproate, and lithium levels for therapeutic drug monitoring. It is an active technique where-in
the subdermal drug is driven to the surface of the skin by application of low intensity electric
current through skin (10, 24-26).
Ultrasound technique has also been used to sample interstitial fluid. This technique involves
permeabilization of skin by ultrasound followed by collection of interstitial fluid by application
of vacuum (10, 27, 28).
1.2.2. Electroporation and transcutaneous sampling (ETS)
Electroporation is considered to be one of the promising electrically mediated techniques
to enhance drug delivery across the skin involving reversible permeabilization of skin brought
about by application of short electrical pulses. Transient aqueous pathways are created in the
stratum corneum due to the application of high voltage short electrical pulses, which reseal to
regain the barrier property. The recovery of stratum corneum barrier property depends on the
nature, number and pulse voltage applied (29-32).
Electroporation and transcutaneous sampling (ETS) is a noninvasive technique for estimating the
time course of drugs in the dermal extracellular fluid. ETS is a technique of reversible
permeabilization of stratum corneum and sampling of drugs and analytes from the dermal
extracellular fluid by facilitating reverse diffusion of drug in the direction of dermis to stratum
corneum. The principle of ETS is similar to that of microdialysis; in case of microdialysis, the
recovery of the unbound drug from the dermal ECF is determined by the permeability of
4

microdialysis probe membrane whereas in case of ETS, the recovery of unbound drug is
determined by the skin permeability. In ETS, the diffusion of free drug across stratum corneum
is affected only by the free drug concentration in dermal extracellular fluid as the drug bound to
plasma proteins does not diffuse across stratum corneum following electroporation. Previous
studies have reported that electroporation is efficient in transporting molecules up to 10 kDa.
Hence, the transcutaneous flux of the drugs is proportional to the unbound drug concentration in
the dermal extracellular fluid (33-35).
The main objectives of ETS project are:
I.

To develop a simple, noninvasive technique of sampling drugs and analytes from the
dermal extracellular fluid.

II.

To study the time course of drug in the skin following drug administration by different
routes of drug delivery.

5

1.3. Transdermal drug delivery
Transdermal drug delivery involves the transport of drugs due to concentration gradient
from the skin surface into the systemic circulation. Delivery of drugs across the skin provides an
alternative to the conventional oral drug delivery and intravenous administration. The major
advantages of transdermal drug delivery are (36, 37):
a) Readily accessible and large surface area of skin for absorption.
b) Avoidance of hepatic first pass effect and gastrointestinal incompatibility.
c) Minimized side effects due to optimized blood concentration-time profile.
d) Self administration is feasible and patient compliant.
e) Predictable and extended duration of therapeutic activity.
f) Reduced frequency of drug administration.
g) Ease of termination of therapy by simple removal of drug source.
However, transdermal drug delivery has certain limitations like:
a) Stratum corneum layer of skin is the major barrier for delivery of drugs.
b) Suitable for low molecular weight and slightly lipophilic drugs only.
1.3.1. Different approaches to enhance transdermal drug delivery
Passive transdermal drug delivery is limited due to the barrier property of stratum
corneum. The different approaches used to enhance transdermal drug delivery include:
I.
II.

Chemical enhancers/penetration enhancers
Iontophoresis

III.

Electroporation

IV.

Ultrasound/ Sonophoresis

V.

Microneedles
6

Chemical enhancers are widely used for enhancing the permeation of poorly penetrating drug
molecules through the skin. Numerous compounds like sulphoxides, azones, pyrrolidones,
alcohols, glycols, surfactants, and terpenes have been found to be efficient in enhancing the
transdermal drug delivery. The main mechanisms for enhanced transdermal drug delivery by
chemical enhancers or penetration enhancers include increased solubility of drug in the donor
formulation, increased partitioning into the stratum corneum, fluidization of lipid bilayers, and
disruption of intracellular proteins (38, 39).
Iontophoresis is a physical technique used for enhancing the transdermal drug delivery. It
involves the application of mild electric current, which aids in the movement of charged drug
molecules across the skin. The amount of drug delivered depends on the electric current applied,
duration of application and the area of skin surface to which current is applied. The main
mechanisms contributing to iontophoresis are electrophoresis and electroosmosis. Iontophoresis
approach had been used for enhancing transdermal delivery of drugs like 5-fluorouracil, sodium
nonivamide, lidocaine hydrochloride, dexamethasone sodium phosphate, fentanyl, timolol, and
acyclovir. The maximum current density that can be applied clinically is limited to 0.5 mA/cm2
(40-46).
Electroporation is a technique that involves transient structural perturbation of lipid bilayer
membranes due to the application of high voltage (60-120 V) electrical pulses. Electroporation
leads to the formation of transient aqueous pathways within the stratum corneum and the main
mechanisms for enhanced transdermal drug delivery are electrophoresis and enhanced diffusion.
The factors affecting transdermal drug delivery by electroporation include the pulse voltage,
number of pulses, pulse length, physicochemical properties of drug and formulation of drug
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reservoir. Electroporation was shown to enhance transport of drugs like timolol, metoprolol,
fentanyl, calcein, calcitonin, and heparin (29, 31, 34, 47-51).
Sonophoresis is a technique of enhancing transdermal drug delivery by application of low
frequency ultrasound (20-100 kHz) on the skin. The mechanisms leading to enhanced drug
transport by sonophoresis include cavitation, thermal effects, induction of convective transport,
and mechanical effects. Sonophoresis was shown to increase the transdermal delivery of drugs
like lidocaine, corticosterone, estradiol, cyclosporine, and insulin (52-58).
Microneedle system consists of an array of micron sized needles which will penetrate the
epidermal region of the skin to create microchannels Based on application, microneedles used
can be solid microneedles or hollow microneedles. The effect of microneedles depends on the
type of needles used, fabrication, needle length, width, shape, and force of insertion.
Microneedles have been used to enhance the transdermal transport of compounds like
naltrexone, calcein, insulin, and DNA vaccination (59-64).
1.3.2. Novel approaches to enhance transdermal drug delivery
The two techniques that we have developed in our laboratory for efficient transdermal
drug delivery are
1. ChilDrive Iontophoresis
2. Magnetophoresis
ChilDrive iontophoresis is a technique of combining regional cutaneous hypothermia with
iontophoresis for enhancing the transdermal delivery of drugs to deeper musculoskeletal tissues.
Magnetophoresis is a technique of enhancing transdermal drug delivery by the application of
magnetic field strength.
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CHAPTER-2
DERMAL DRUG LEVELS OF ANTIBIOTIC (CEPHALEXIN) DETERMINED BY
ELECTROPORATION AND TRANSCUTANEOUS SAMPLING (ETS) TECHNIQUE

2.1. ABSTRACT
The purpose of this project was to assess the validity of a novel electroporation and
transcutaneous sampling (ETS) technique for sampling cephalexin from the dermal extracellular
fluid (ECF). This work also investigated the plausibility of using cephalexin levels in the dermal
ECF as a surrogate for the drug levels in the synovial fluid. In vitro and in vivo studies were
carried out using hairless rats to assess the workability of ETS. Cephalexin (20 mg/kg) was
administered (i.v.) through tail vein and the time course of drug concentration in the plasma was
determined. In the same rats, cephalexin concentration in the dermal ECF was determined by
ETS and microdialysis techniques. In a separate set of rats, only intraarticular microdialysis was
carried out to determine the time course of cephalexin concentration in the synovial fluid. The
drug concentration in the dermal ECF determined by ETS and microdialysis did not differ
significantly from each other and so as were the pharmacokinetic parameters. The results provide
validity to the ETS technique. Further, there was a good correlation (~0.9) between synovial
fluid and dermal ECF levels of cephalexin indicating that dermal ECF levels could be used as a
potential surrogate for cephalexin concentration in the synovial fluid.
Keywords: Electroporation; Transcutaneous sampling; Microdialysis; Pharmacokinetics.
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2.2. OBJECTIVES AND SIGNIFICANCE
The objectives of this study are:
I.
II.

To determine if ETS could be utilized for sampling of cephalexin from dermal ECF.
To ascertain if the dermal ECF levels can serve as a surrogate for synovial fluid levels of
cephalexin.

The most commonly occurring infections in people are skin infections. Particularly, children and
elderly people are mostly affected with skin infections due to lack of potent immune system.
Cephalosporins are most widely used for treatment of skin infections because of their safety
profiles (65-67). Cephalexin, a first generation cephalosporin antibiotic is mostly used because of
its activity against both the gram-positive and gram-negative microorganisms (68). In addition to
treatment of skin infections, cephalexin is also commonly used to treat the articular infections
(69, 70). Achieving therapeutically active drug levels at the site of infection is vital for any
antibiotic therapy. In general, when the infection is situated in the central pharmacokinetic
compartment, the activity of the drug is determined by the unbound drug concentration in the
plasma. However, in case of infections in the peripheral tissues such as skin and articular region,
it is the time course of concentration of unbound antibiotic in the respective tissue fluids, which
is crucial for successful treatment. In such cases monitoring the drug levels in the plasma may
not reflect the actual levels in the affected tissue. Therefore, the time course of antibiotics in the
affected tissue needs to be monitored for determining the frequency and dose of drug
administration from the safety and efficacy perspectives of the antibiotic therapy (71-75).

10

2.3. MATERIALS AND METHODS
2.3.1. Chemicals
Cephalexin hydrate was purchased from Sigma-Aldrich Inc. (St. Louis, MO), Phosphate
buffered saline (PBS, pH 7.4) premixed powder was obtained from EMD Chemicals
(Gibbstown, NJ), and all other chemicals were obtained from Fischer Scientific (Fairway, NJ).
2.3.2. In vitro experimental setup
The in vitro diffusion studies were carried out in Franz diffusion cells (FDC) (Logan
Instruments Ltd., Somerset, NJ) using hairless rat skin excised from the abdomen region.
Hairless rat skin is known to be a good model for topical and transdermal drug delivery studies
due to the similarity between the rat and human skin with respect to lipid content and water
uptake properties (76). Moreover, a good correlation of permeation data between the hairless rat
model and human skin models has been reported by several research groups in the past (77). The
skin was mounted on the diffusion cell in such a way that the epidermis side of the skin was in
contact with upper sampling compartment and dermal side with the lower reservoir
compartment. The active diffusion area of FDC was 0.64 cm2. Ag/AgCl electrode wires of 0.5
mm diameter (Alfa Aesar, Ward Hill, MA) made in form of circular rings were placed 2 mm
away from skin in both sampling and reservoir compartments. The sampling and the reservoir
compartments were filled with 0.4 and 5 ml PBS respectively and the skin was allowed to
equilibrate for 1 h. The AC electrical resistance of the epidermis was measured by placing a load
resistor RL (100 kΩ) in series with the epidermis. The voltage drop across the whole circuit (VO)
and across the skin (VS) was measured using an electrical set up consisting of a waveform
generator and a digital multimeter (Agilent Technologies, Santa Clara, CA). For measuring
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resistance, voltage of 100 mV was applied at 10 Hz and the skin resistance in kΩ was
approximated from the formula:

Rs =

VS RL
VO − VS

(1)

where RS is the skin resistance and RL is the load resistor in kΩ. The piece of skin which had a
resistance greater than 20 kΩ.cm2 was used for the experiment.
2.3.3. In vitro transcutaneous sampling studies
The sampling compartment was replaced with 0.4 ml of PBS (pH 7.4) and the reservoir
compartment was filled with 5 ml of cephalexin solution prepared in PBS (5-40 µg/ml). Thirty
square electrical pulses each of 10 ms duration at 120 V/cm2, 1 Hz was applied using ECM 830
Electro Square Porator (BTX Harvard apparatus, Holliston, MA). The electrical resistance was
measured immediately after application of electrical pulses to ensure skin permeabilization. PBS
from the sampling compartment was withdrawn 15 min after application of electrical pulses and
the amount of cephalexin sampled was analyzed by HPLC.
2.3.4. Ex vivo plasma protein binding
The blood was collected by cardiac puncture in rats and the plasma was separated by
centrifugation at 2000g at 4 ºC. Rat plasma was spiked with drug to provide concentration
ranging from 1-20 µg/ml. The spiked plasma samples were thoroughly mixed by vortexing and
allowed to equilibrate for 12 h at 4 ºC. After equilibration, protein free plasma was obtained by
using ultra filtration (Millipore Centrifree® filtration units) by centrifugation of 0.5 ml of plasma
at 2000g for 20 min (71, 76). The amount of unbound drug present in the filtrate was measured
by HPLC after suitable dilution with PBS.
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2.3.5. In vivo studies
The in vivo experimental procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) at the University of Mississippi (Protocol#07-004). The in vivo studies
were carried out in hairless rats (Taconic, Hudson, Newyork) (250-300 g) under ketamine (80
mg/kg) and xylazine (10 mg/kg) anesthesia administered intraperitoneally.
Plasma sampling, ETS and microdialysis sampling was carried out in the same group of rats
(n=6). The samples by all three procedures were obtained at the same time points in each rat
simultaneously. Cephalexin solution of 20 mg/kg prepared in sterile isotonic saline was
administered by i.v. into tail vein as a bolus injection.
2.3.5.1. Cutaneous microdialysis
A 20G needle was inserted intradermally through a distance of 1 cm and a linear
microdialysis probe of 5 mm membrane length and 30 kDa cutoff molecular weight (BASi, West
Lafayette IN) was inserted through this needle and the needle was withdrawn leaving the probe
implanted in the dermal tissue. The inlet tube was connected to an injection pump (BASi, West
Lafayette, IN) and PBS was perfused at 2 µl/min flow rate for 30 minutes for equilibration. Two
samples were collected before drug administration. The drug was injected by i.v through the tail
vein after equilibration of the probe. Subsequently, the microdialysis samples were collected
continuously at every 15 minutes interval including at time points corresponding to ETS and
plasma sampling at 30, 60, 120, 180, 240, 300 and 360 min.
2.3.5.2. Electroporation and transcutaneous sampling
Prior to the drug administration, a custom made sampling cell was fixed using an
adhesive (Krazy glue, Elmers products Inc, Ohio) on the back of the rats (Figure 2-1). The
sampling cell was fitted with an Ag/AgCl electrode and the counter electrode was secured just
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adjacent to the cell on the surface of the skin using a micropore surgical tape (3M Healthcare,
MN).

Figure 2-1. Diagrammatic representation showing an experimental setup of electroporation and
transcutaneous sampling in hairless rats.

The skin was hydrated with 100 µl of saline for 5 min before each sampling and was replaced
with 100 µl of PBS (sampling buffer). One blank sample was collected before drug
administration, and subsequent samples were collected at (30, 60, 120, 180, 240, 300 and 360
min). For ETS procedure, 30 electrical pulses each of 10 ms duration at 120 V/cm2, 1 Hz was
applied and the sampling fluid remained in the chamber for 15 min after pulsing.
2.3.5.3. Plasma pharmacokinetics of drug
For plasma pharmacokinetic studies, 100 µl of blood was collected by retro-orbital
bleeding before injection of drug and before each episode of transcutaneous sampling and
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cutaneous microdialysis. The blood samples were diluted with 200 µl of PBS and plasma was
separated followed by protein precipitation and the plasma drug content was analyzed by HPLC.
2.3.5.4. Intraarticular microdialysis
In another set of rats (n=6), intraarticular microdialysis was carried out to determine the
amount of cephalexin present in the synovial fluid. After anaesthetizing the rats, the hind limb
was held in a fixed position and a 20G needle was passed through the knee joint capsule lateral
to the patellar ligament and a linear microdialysis probe of 5 mm length and 30 kDa cut off
molecular weight (BASi, West Lafayette, IN) was inserted through the needle (78, 79). The
needle was withdrawn leaving the probe implanted in the synovial cavity. PBS was perfused for
30 min prior to drug administration for equilibration at flow rate of 2 µl/min. Cephalexin
solution (20 mg/kg) was administered through the tail vein and microdialysis perfusion was
continued for 6 h with samples collected for 15 min interval including at time points
corresponding to ETS and cutaneous microdialysis sampling.
In case of both cutaneous and intraarticular microdialysis, the probe recovery was determined in
vivo by using retrodialysis method (80-82). For this, the probe was first equilibrated by perfusing
PBS at 2 µl/min for 30 min; followed by drug solution of known concentration for 30 min. After
equilibration, dialysate was collected for 15 min interval at 15, 30 and 45 min and the average
recovery of three time points was considered. The in vivo recovery rate was calculated using the
formula:
Recovery ሺ%ሻ=100- ቀConcentration of perfusate X 100ቁ
Concentration of dialysate
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(2)

2.3.6. Analytical method
The amount of cephalexin present in plasma, ETS and microdialysis samples were
analyzed by HPLC using Symmetry® C18 column (4.6 x 150 mm) with UV detection at 254 nm.
Mobile phase consisted of a mixture of methanol and 2.5 mM sodium phosphate buffer, pH 5.6
(20:80 v/v) and the flow rate was 1 ml/min. The sensitivity of the method was 10 ng/ml and
linearity was between 10-1000 ng/ml (R2=0.99). To the plasma samples, equal volume of
acetonitrile was added to precipitate proteins and then centrifuged at 2000g for 10 min at room
temperature and the supernatant was analyzed for drug content (83, 84). ETS and microdialysis
samples were centrifuged and directly injected into HPLC system.
2.3.7. Data Analysis
The plasma pharmacokinetic parameters were calculated based on two compartment
model represented by the equation:
C = Ae-αt + Be-βt

(3)

where A, B are the pre-exponential constants, α is the distribution rate constant, β is the
elimination rate constant. The values of α, β, A and B are derived from curve fitting of
experimental data. The elimination half life (t1/2) was calculated using the formula 0.693/β and
area under the curve (AUC0-6h) was calculated using the trapezoid rule. The pharmacokinetic
parameters in case of dermal ECF and synovial fluid were calculated using non compartmental
pharmacokinetic model.
The statistical analysis was carried out using GraphPad Instat 3 software and the unpaired t-test
was selected for comparing the parameters obtained from ETS and microdialysis techniques.
P<0.05 was considered as level of significance. From Pearsons correlation, R2 and P-value were
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calculated using Pearson Correlation (v1.0.3) in Free Statistics Software (v1.1.23-r1). The data
points shown in graphs are an average of 6 trials with error bars representing standard deviation.
2.4. RESULTS AND DISCUSSION
Calibration of ETS was carried out in vitro using freshly excised hairless rat skin model.
Known concentrations of drug were placed in the reservoir compartment and the drug was
sampled following electroporation. The amount of drug diffused in 15 min following application
of electrical pulses was plotted against respective reservoir concentrations (5-40 µg/ml) as
represented in Figure 2-2.
The linear relationship (R2=0.96) between the amount of drug sampled and the reservoir drug
concentration implies that the ETS samples would potentially represent the subdermal drug
concentration. The percentage recovery by ETS can be obtained by (slope X 100) from Figure 22 and was found to be 3.06±0.2%. In control (across the untreated skin) the amount of drug
sampled was less than detectable levels. In case of electroporation trials, the resistance of skin
dropped ~74±8% whereas in case of control set of experiments, electrical resistance of skin did
not change significantly. The recovery of electrical resistance of electroporated skin was
insignificant within the sampling duration of 15 min, which is in agreement with previous reports
in case of ETS across the rat skin and porcine epidermis (74, 85).
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Amount of cephalexin sampled (µg/ml)
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Figure 2-2. Correlation between cephalexin concentration (5-40 µg/ml) in the reservoir
compartment and cephalexin sampled by ETS across hairless rat skin in vitro (y=0.03x,
R2=0.96).

The plasma protein binding of cephalexin revealed that the fraction of cephalexin bound to
plasma was 10.2±2.6% at concentrations between 1-20 µg/ml. Low protein binding of
cephalexin is considered to be one of the major reasons for its extensive distribution into the
peripheral tissues. The protein binding values were in agreement with 12.4% that was reported
by Tsai et al (68).
The concentration time profile of cephalexin in plasma and dermal extracellular fluid
(determined by ETS and cutaneous microdialysis) samples following i.v. administration of
cephalexin (20 mg/kg) is shown in Figure 2-3.
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Figure 2-3. Time course of cephalexin in rat plasma (●) determined by blood sampling and
dermal ECF determined by microdialysis (■) and ETS (▲) tecniques following i.v. bolus
administration of 20 mg/kg of cephalexin.

The plasma concentration versus time data of cephalexin could be described by a two
compartment model (86). The pharmacokinetic parameters calculated for plasma drug
concentration-time profile are given in Table 2-1. The plasma drug concentrations reported in
this project are comparable to that reported by Tsai et al in rats considering the difference in dose
between the two studies. The plasma elimination half life of cephalexin in the current study was
104.59±28.61 min (1.74±0.47 h) which agrees well with the elimination half life (1.4±0.81 h)
reported by Padoin et al (68, 86).
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Table 2-1. Pharmacokinetic parameters derived from the plasma concentration-time data after i.v
bolus administration of 20 mg/kg of cephalexin in hairless rats.

Parameter

i.v. bolus

A (µg/ml)

52.35±1.41

B (µg/ml)

11.89±1.04

t1/2 (min)

104.59±28.61

α (1/min)

0.03355±0.004

β (1/min)

0.00688±0.001

AUC0-6h (µg.min/ml)

3160.93±250.35

The recovery of cephalexin by the microdialysis probe in the cutaneous tissue was found to be
21.14±5.26% whereas the recovery of cephalexin by ETS was only about 3.06±0.2% which is
about 7-fold less than that of microdialysis. Although ETS has the advantage of being
noninvasive as opposed to microdialysis, the later has the limitation with the amount of drug that
could be sampled from the dermal ECF. Nevertheless, recovery could likely be improved by
using more vigorous electrical protocol and/or by increasing the sampling duration. In both
microdialysis as well as ETS techniques, the amount of cephalexin present in the dermal ECF in
rats was calculated using the amount sampled and the corresponding recovery values as follows.

Dermal ECF concentration=

sample concentration
percentage recovery

(4)

In the current study, the point to point comparison of the drug concentration in the dermal
extracellular fluid and the pharmacokinetic parameters, i.e. Cmax, Tmax, AUC0-6h and t1/2,
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determined by ETS and microdialysis techniques did not differ significantly (unpaired t-test,
P<0.05) (Table 2-2). This provides validity to the ETS technique of sampling cephalexin.
Table 2-2. Mean pharmacokinetic parameters of cephalexin determined by ETS, microdialysis
techniques following administration of 20 mg/kg by i.v bolus in hairless rats.
Parameter

ETS

Microdialysis

P-value

Tmax (min)

120

120

--

Cmax (µg/ml)

13.09±1.92

12.64±1.90

0.39

AUC0-6h(µg.min/ml)

2512.35±250.14

2473.66±202.43

0.42

t1/2 (min)

106.61±17.81

96.37±12.33

0.22

The amount of drug present in the synovial fluid is shown in Figure 2-4 and the pharmacokinetic
parameters are given in Table 2-3. In this case, the in vivo microdialysis probe recovery was
found to be 10.64±3.44%. The Cmax in case of synovial fluid (3.23±0.58 µg/ml) was four fold
less than the dermal ECF (~13.09 µg/ml). This data suggests that relatively higher doses of
cephalexin would be required to achieve effective drug levels in the synovial fluid.
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Figure 2-4. Concentration-time profile of cephalexin in synovial fluid obtained by intraarticular
microdialysis after administration of 20 mg/kg of drug by i.v. bolus.

Table 2-3. Mean pharmacokinetic parameters of cephalexin determined by intraarticular
microdialysis in the synovial fluid following administration of 20 mg/kg by i.v bolus in hairless
rats.

Parameter

Synovial fluid

Tmax (min)

120

Cmax (µg/ml)

3.233±0.58

t1/2 (min)

96.215±8.08

AUC0-6h (µg.min/ml)

654.10±101.35
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The drug levels from synovial fluid were plotted against drug levels in dermal ECF obtained by
ETS and microdialysis techniques. A good correlation of 0.92 (P=0.00029) and 0.91
(P=0.00047) was observed between the drug levels in synovial fluid and dermal ECF obtained
from ETS (Figure 2-5) and microdialysis (Figure 2-6).

Concentration of cephalexin in dermal ECF
(µg/ml ) (ETS)

18
16
14
12
10
8
6
4
2
0
0

1

2

3

4

Concentration of cephalexin (µg/ml) in synovial
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Figure 2-5. Correlation between cephalexin levels in dermal ECF obtained from ETS with that
of synovial fluid drug levels (y=3.78x, R2=0.92).

23

Concentration of cephalexin in dermal ECF
(µg/ml) (microdialysis)

16
14
12
10
8
6
4
2
0
0
1
2
3
4
Concentration of cephalexin (µg/ml) in synovial
fluid

Figure 2-6. Correlation between cephalexin levels in dermal ECF obtained from microdialysis
with that of synovial fluid drug levels (y=3.72x, R2=0.91).
From this relationship, it could be said that in rats, the drug level in the skin represents ~3.7X of
that in the synovial fluid. Establishing such correlation between the dermal ECF and the
concentration of drug in internal tissues would help in monitoring the drug levels of peripheral
tissues which are extremely difficult to access. From the results of this experiment it appears that
dermal ECF levels of cephalexin could be used as potential surrogate for cephalexin levels in the
synovial fluid.
ETS is a noninvasive method of cutaneous drug sampling and is expected to be relatively safer
than microdialysis method. However, there are concerns about potential skin damage due to the
application of electrical pulses. Many research groups have evaluated the safety of skin
electroporation in animal models and human subjects. Vanbever et al. have reported that
24

reversible mild skin reactions occurred following the application of 15 electrical pulses of 250 V
and 200 ms in vivo in hairless rats (87). Wong et al. have shown that electroporation can be
carried out in humans without causing pain at 150 V, 1 ms, 60 pulses by using microelectrode
array (88). The protocol that was applied in current experiments was 120 V, 30 square pulses
each of 10 ms duration which is rather mild than the protocols applied on human subjects in
other studies. The extent of skin damage depends on the applied electrical protocol and the
electrode design. Therefore the optimum electrical protocols need to be evaluated in vivo for
tolerability, morphological, histological, and biochemical changes in the skin before
implementation in clinical practice.
2.5. CONCLUSIONS
ETS is a potential noninvasive technique that could be developed for sampling of drugs
from the skin tissue. However, the major limitation of the technique is low recovery, which
limits the application of the technique to drugs which are less protein bound and which are
present considerably in high amounts in the dermal ECF. One of the most interesting outcomes
of the present work was that the dermal ECF concentration of cephalexin correlated well with the
concentration in synovial fluid.
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CHAPTER-3
TRANSCUTANEOUS SAMPLING OF CIPROFLOXACIN AND
8-METHOXYPSORALEN BY ELECTROPORATION (ETS TECHNIQUE)

3.1. ABSTRACT
The novel technique of transcutaneous sampling of drugs by electroporation was
developed to study the dermatokinetics of ciprofloxacin and 8-methoxypsoralen. The selected
drugs differ in their aqueous solubility and also with respect to the extent of protein binding.
Ciprofloxacin (15 mg/kg) was administered i.v. through tail vein whereas 8-methoxypsoralen (5
mg/kg) was given by oral administration in hairless rats and the time course of drug
concentration in the plasma was determined. Drug concentration in the dermal extracellular fluid
(ECF) was determined by ETS and microdialysis sampling techniques. The drug concentration in
the dermal ECF determined by ETS and microdialysis did not differ significantly from each
other and so as were the pharmacokinetic parameters. The results show that ETS can be utilized
as a potential technique for sampling of drugs from the dermal extracellular fluid.
Keywords:

Electroporation;

Transcutaneous

Pharmacokinetics; Extracellular fluid.
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3.2. OBJECTIVES AND SIGNIFICANCE
The objectives of the study are:
I.

To assess the feasibility of ETS technique for drugs of different physicochemical
properties.

II.

To assess the workability of ETS technique, when drugs are administered via different
routes.

Two drugs ciprofloxacin and 8-methoxypsoralen which possess different physicochemical
properties and also differ in their extents of protein binding are selected as model drugs. For the
purpose of assessing the validity of the technique, the two drugs were administered by different
routes in this project (Ciprofloxacin by i.v. bolus and 8-methoxypsoralen by oral route).
Ciprofloxacin, a broad spectrum antibacterial agent belonging to the group of fluoroquinolones is
effective against microbial infections localized in the skin. The time course of ciprofloxacin in
the skin needs to be monitored for determination of the frequency and dose from safety and
efficacy perspectives (71, 89-91).
8-methoxypsoralen, a furocoumarinic is used in conjunction with UV radiation (PUVA therapy)
for the treatment of dermatoses like vitilgo and psoriasis (92-94). The effectiveness of 8methoxypsoralen depends on ultraviolet-A irradiation and optimum response will be elicited
only when the drug concentration in skin is over the effective concentration. For this reason, it is
imperative to determine drug concentration in skin to achieve better PUVA therapy (95-97).
3.3. MATERIALS AND METHODS
3.3.1. Chemicals
Ciprofloxacin Hydrochloride, 8-Methoxypsoralen were purchased from Sigma-Aldrich
Inc (St.Louis, MO), Phosphate buffered saline (PBS, pH 7.4) premixed powder was obtained
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from EMD Chemicals (Gibbstown, NJ), and all other chemicals were obtained from Fischer
Scientific (Fairway, NJ).
3.3.2. In vitro transcutaneous sampling studies
The in vitro diffusion studies were carried out in Franz diffusion cells (FDC) (Logan
Instruments Ltd., Somerset, NJ) using hairless rat skin excised from the abdomen region.
Hairless rat skin is considered to be a good model for topical and transdermal drug delivery
studies due to the similarity between the rat and human skin with respect to lipid content and
water uptake properties (76). Moreover, a good correlation of permeation data between the
hairless rat model and human skin models have been reported by several research groups in the
past (77). The skin was mounted on the diffusion cell in such a way that the epidermis side of the
skin was in contact with upper sampling compartment and dermal side with the lower reservoir
compartment. The active diffusion area of FDC was 0.64 cm2. Ag/AgCl electrode wires of
0.5 mm diameter (Alfa Aesar, Ward Hill, MA) made in the form of circular rings were placed
2 mm away from skin in both sampling and reservoir compartments. The sampling compartment
and the reservoir compartment were filled with 0.4 and 5 ml PBS, respectively and the skin was
allowed to equilibrate for an hour. The AC electrical resistance of the epidermis was measured
by placing a load resistor RL (100 kΩ) in series with the epidermis. The voltage drop across the
whole circuit (VO) and across the skin (VS) was measured using an electrical set up consisting of
a waveform generator and a digital multimeter (Agilent Technologies, Santa Clara, CA). For
measuring resistance, voltage of 100 mv was applied at 10 Hz and the skin resistance in kΩ was
approximated. The piece of skin, which had a resistance greater than 20 kΩ.cm2 was used for the
experiment.
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Later, the sampling compartment was replaced with fresh 0.4 ml of PBS and reservoir
compartment was filled with 5 ml of ciprofloxacin solution prepared in PBS (2.5-40 µg/ml). In
case of 8-methoxypsoralen, the sampling compartment was replaced with PBS:ethanol (50:50)
and the reservoir compartment was filled with 5 ml of 8-methoxypsoralen solution (2.540 µg/ml) prepared in PBS:ethanol (50:50). Thirty square electrical pulses each of 10 ms
duration at 120 V/cm2, 1 Hz was applied using ECM 830 Electro Square Porator (BTX Harvard
apparatus, Holliston, USA). The electrical resistance of the skin was measured immediately after
application of the electrical pulses to ensure skin permeabilization. The solution from the
sampling compartment was withdrawn 15 min after application of electrical pulses and the
amount of drug was analyzed by HPLC.
3.3.3. Ex vivo plasma protein binding
The blood was collected by cardiac puncture in rats and the plasma was separated by
centrifugation at 2000g at 4 °C. Rat plasma was spiked with drug to prepare samples of
concentration ranging from 1 to 40 µg/ml. The spiked plasma samples were thoroughly mixed by
vortexing and allowed to equilibrate for 12 h at 4 °C. After equilibration, protein free plasma was
obtained by carrying out ultra filtration (Millipore Centrifree® filtration units) by centrifugation
of 0.5 ml of plasma at 2000g for 20 min. The amount of unbound drug present in the filtrate was
measured by HPLC after suitable dilution with PBS (74, 98).
3.3.4. In vivo studies
The in vivo experimental procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) at the University of Mississippi (Protocol#07-004). The in vivo studies
were carried out in hairless rats (Taconic, Hudson, Newyork) (250-300 g) under ketamine (80
mg/kg) and xylazine (10 mg/kg) anesthesia administered intraperitoneally.
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Blood sampling, ETS and microdialysis sampling was carried out in the same group of rats
(n=6).The samples by all three procedures were obtained at the same time points in each rat
simultaneously. Ciprofloxacin solution (150-180 µl) of 15 mg/kg prepared in sterile isotonic
saline was administered by i.v. into tail vein as a bolus injection, whereas in case of 8methoxypsoralen, solution (415-500 µl) of 5 mg/kg prepared in 50:50 of PBS:ethanol was given
by oral gavage using a ball ended feeding needle.
3.3.4.1. Cutaneous microdialysis
For cutaneous microdialysis, a 20G needle was inserted intradermally through a distance
of 1 cm and penetration depth of 2 mm. A linear microdialysis probe of 5 mm membrane length
and 30 kDa cutoff molecular weight (BASi, West Lafayette IN) was inserted through this needle
and the needle was withdrawn leaving the probe implanted in the dermal tissue. The proper
placement of probe in the dermis was confirmed by making an incision at the site of probe
implantation after completion of the study. Any experiment, in which the probe was not placed
horizontally at the intended depth was not considered.
The inlet tube was connected to an injection pump (BASi, West Lafayette, IN) and perfusion was
set to a flow rate of 2 µl/min. The probe was equilibrated for 30 min (99-101). The perfusate was
PBS for studies involving ciprofloxacin and PBS:ethanol (50:50) for 8-methoxypsoralen. Two
samples were collected before drug administration. The drug was administered after equilibration
of the probe. Subsequently the microdialysis samples were collected continuously at every 15
min interval including at time points corresponding to ETS and plasma sampling at 30, 60, 120,
180, 240, 300 and 360 min. The microdialysis probe recovery was determined in vitro by placing
microdialysis probe in PBS containing known drug concentration and perfusing the probe with
PBS (for ciprofloxacin) and 50:50 PBS:ethanol (for 8-methoxypsoralen) at flow rate of 2 µl/min.
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The dialysate coming out of the probe is collected every 15 min and analyzed for drug content
(102, 103). The in vitro recovery rate was calculated using the formula:
% Relative recovery= ቀ

ቁ X 100

concentration of dialysate
concentration of sample

(5)

3.3.4.2. Transcutaneous sampling by electroporation
A custom made sampling cell was fixed using an adhesive (Krazy glue, Elmers products
Inc., Ohio) on the back of the rats. The sampling cell was fitted with a Ag/AgCl electrode and
the counter electrode was secured just adjacent to the cell on the surface of the skin using a
micropore surgical tape (3 M Healthcare, MN). The skin was hydrated with 100 µl of saline for
5 min before each sampling and was replaced with 100 µl of sampling buffer (PBS for
ciprofloxacin, PBS:ethanol (50:50) for 8-methoxypsoralen). One blank sample was collected
before drug administration, and subsequent samples were collected at 30, 60, 120, 180, 240, 300
and 360 min. For ETS procedure, thirty square electrical pulses each of 10 ms duration at
120 V/cm2, 1 Hz was applied and the sampling fluid remained in the chamber for 15 min after
pulsing.
3.3.4.3. Plasma pharmacokinetics of drugs
For plasma pharmacokinetic studies, 100 µl of blood was collected by retro-orbital
bleeding before administration of drug and before each episode of transcutaneous sampling and
cutaneous microdialysis. The blood samples were diluted with 200 µl of PBS and plasma was
separated by centrifugation at 2000g. In case of ciprofloxacin, plasma samples were subjected to
protein precipitation with equal volume of 0.5 M perchloric acid, followed by centrifugation at
10000g for 10 min and drug content was analyzed by HPLC (90). 8-methoxypsoralen in the
plasma was extracted with methylene chloride for 30 min followed by centrifugation at 5000g at
4 ○C for 10 min, the organic phase was separated and evaporated to dryness at room temperature
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under nitrogen and the residue was dissolved in PBS:ethanol (50:50) and analyzed by HPLC
(104).
3.3.5. Analytical method
The amounts of ciprofloxacin and 8-methoxypsoralen present in plasma, ETS and
microdialysis samples were analyzed by high performance liquid chromatography. The HPLC
system (Waters, MA) consisted of a chromatographic pump (Waters 1525) and an autosampler
(Waters 717 plus).
Analysis of ciprofloxacin samples were carried out using a fluorescence detector (Waters 2475)
at an excitation wavelength of 278 nm and emission wavelength of 445 nm. Symmetry® C18
column (4.6 x 150 mm) was used and the mobile phase consisted of a mixture of acetonitrile and
0.1 M aqueous monopotassium phosphate solution adjusted to pH 2.5 with orthophosphoric acid
(15:85 v/v) with flow rate of 2 ml/min (90). The linearity range was between 1-1000 ng/ml
(R2=0.99).
Analysis of 8-methoxypsoralen samples were carried out using a UV detector (Waters 2487) at
248 nm using Symmetry® C18 column (4.6 x 150mm). The mobile phase consisted of a mixture
of methanol, acetonitrile and water (2:30:68) and the flow rate was 1ml/min (104, 105).
3.3.6. Data analysis
The

pharmacokinetic

parameters

were

calculated

using

non

compartmental

pharmacokinetic model. The terminal elimination rate constant (λz) was determined from the
slope of terminal exponential phase of the logarithmic plasma concentration-time curve. The
elimination half life (t1/2) was calculated using 0.693/λz .The area under the curve (AUC0-t) was
caclulated using the trapezoidal rule and AUC0-∞ was obtained by adding Clast/λz to AUC0-t. In
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case of 8-methoxypsoralen, the maximum plasma concentration (Cmax ) and the time to reach
maximum plasma concentration (Tmax ) were determined from the concentration-time curves.
The statistical analysis was carried out using GraphPad Instat 3 software and the t-test was
selected for comparing the parameters obtained from ETS and microdialysis techniques. P<0.05
was considered as level of significance. The data points shown in graphs are an average of 6
trials with error bars representing standard deviation.
3.4. RESULTS AND DISCUSSION
Solubility of drug in the sampling fluid is one of the key determinants of recovery of drug
in case of both ETS and microdialysis. PBS was found to be an appropriate solvent for sampling
ciprofloxacin. However, in the case of 8-methoxypsoralen, the recovery was poor with PBS
which was likely due to the low water solubility of 8-methoxypsoralen (water solubility of 8methoxypsoralen is ~55.8 µg/ml). The recovery of 8-methoxypsoralen was improved with 50:50
PBS:ethanol system in both ETS and microdialysis techniques.
Electroporation leading to permeabilization of the skin is indicated by the drastic drop in
electrical resistance of the skin. The drop in electrical resistance has been reported to be due to
formation of transient aqueous pathways in the lipid domain of the stratum corneum. The
aqueous pathways reseal and the skin will regain its barrier property (thus its original electrical
resistance). The extent of drop in electrical resistance and the duration required for the skin to
recover is determined by the applied electrical protocol. With the protocol of 120 V, 10 ms, 30
pulses applied in this project, the drop in skin resistance was ~70±5%. There was no significant
recovery in skin resistance during the sampling time of 15 min. However, the skin resistance
recovered within few hours reflecting the fact that the electrical protocol was not too aggressive
to bring about irreversible impairment of the skin barrier. This was in agreement with the
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observations in previous studies carried out across the rat skin and porcine epidermis (35, 74,
85).
Transcutaneous sampling was also carried out across the untreated skin (did not apply electrical
pulses) which served as control set of experiment. In case of untreated skin (control samples),
detectable level of drugs could not be sampled within the sampling duration of 15 min. In case of
ETS, detectable amounts of drug was sampled even at low reservoir drug concentrations. The
amount of drug sampled in 15 min following application of electrical pulses was plotted against
the corresponding reservoir drug concentrations (Figure 3-1 and 3-2).
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Figure 3-1. Correlation between ciprofloxacin concentration (2.5-40 µg/ml) in the reservoir
compartment and the amount sampled by ETS across hairless rat skin in vitro (y=0.048x,
R2=0.96).
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A linear relationship (R2=0.96 and 0.98 for ciprofloxacin and 8-methoxypsoralen respectively)
was observed between the amount of drug sampled and the reservoir drug concentration,
indicating that the subdermal drug concentration can be represented by ETS samples. The
percentage recovery by ETS (slope X 100) was 4.8±0.8% and 7.6±1.3% for ciprofloxacin and 8methoxypsoralen respectively. The recovery of 8-methoxypsoralen was less (~0.5%) when ETS

Amount of 8-methoxypsoralen sampled (µg/ml)

was carried out with PBS alone.
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Figure 3-2. Correlation between 8-methoxypsoralen concentration (2.5-40 µg/ml) in the
reservoir compartment and the amount sampled by ETS across hairless rat skin in vitro
(y=0.076x, R2=0.98).

The free drug present in the blood plasma equilibrates rapidly with the skin ECF. In otherwords,
the extent of distribution of drug into peripheral tissues is known to be determined predominantly
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by the plasma protein binding. Generally, the drugs that show high protein binding penetrate less
into the peripheral compartment. Ex vivo plasma protein binding studies were carried out for
both ciprofloxacin and 8-methoxypsoralen to assess the relationship between the protein binding
and tissue penetration. The plasma protein binding of ciprofloxacin was found to be
20.65±3.93% at concentrations between 1-40 µg/ml which was in aggreement with 16-40%
reported by other research groups (106-108). The fraction of 8-methoxypsoralen bound to
plasma was 80.97±6.85%. This was comparable to 91.4% reported by Pibouin et al (109). The
two drugs chosen for this project differ significantly with respect to their protein binding
property. One of the major objectives of this project was to assess the workability of the ETS
technique in case of drugs which exhibit different extents of protein binding.
The in vitro recovery of ciprofloxacin and 8-methoxypsoralen by microdialysis probe were
found to 3.47±0.35% and 16.41±3.32% respectively. Generally microdialysis is regarded as less
suitable for sampling lipophilic drugs because, microdialysis method of drug sampling involves
perfusion of aqueous sampling fluid through the dialysis probe during which the exchange of
ingredients between the perfusion fluid and tissue fluid takes place. The perfusate liquids are
preferably aqueous and therefore when the drug to be sampled is highly lipophilic, the recovery
of the drug with the aqueous perfusion liquids would be relatively very less (101, 110, 111). It is
not recommended to use organic solvents as the perfusate could alter the dialysis membrane
properties and may also cause potential toxicity to the tissue. However, in this study, we found
that the permeability of the dialysis membrane did not change significantly even after immersing
the membrane for over 24 hours in the 50:50 PBS:ethanol system.
In case of ETS, as the technique is noninvasive and the sampling fluid is in contact with the
tissue for a short period of time during drug sampling, use of hydroalcoholic systems pose
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relatively less severe risk as compared to microdialysis. This shows that ETS technique could be
used to sample even lipophilic drugs, by changing the

the sampling fluid constitution

appropriately. This is considered as one of the the advantages of ETS over microdialysis
technique.
In the current experiments, as the animals were anesthetized, there were no notable irritation
symptoms due to electroporation or microdialysis. There was no inflammation due to application
of electrical pulses or insertion of probe. However, there was slight bleeding during the
implantation of the probe which stopped within 1 or 2 min completely.
From both microdialysis and ETS techniques, the amount of ciprofloxacin and 8methoxypsoralen present in the dermal ECF in rats was calculated using the amount sampled and
the corresponding recovery values as follows:

Dermal ECF concentration=

sample concentration
percentage recovery

(6)

The concentration time profile of ciprofloxacin (15 mg/kg) in plasma and dermal ECF
(determined by ETS and cutaneous microdialysis) following i.v. bolus administration was
represented in Figure 3-3. The pharmacokinetic parametes calculated from non-compartmental
analysis are given in Table 3-1.
The plasma elimination half life of ciprofloxacin in the present study was found to be
124.12±25.99 min. This was comparable to 102.3±26.2 min and 91±8.6 min reported by
Nouaille-Degorce et al. and Tsai et al. respectively (91, 106).
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Figure 3-3. Time course of ciprofloxacin in rat plasma (●-total drug; ♦-unbound drug)
determined by blood sampling and dermal ECF determined by microdialysis (■) and ETS (▲)
techniques following i.v. bolus administration of 15 mg/kg of ciprofloxacin.

Table 3-1. Mean pharmacokinetic parameters of ciprofloxacin (unbound) in plasma and dermal
ECF (determined by ETS and microdialysis) following administration of 15 mg/kg by i.v bolus
in hairless rats.
Parameter

ETS

Microdialysis

Plasma

Tmax (min)

30

30

30

Cmax (µg/ml)

0.906±0.046

0.729±0.196

1.695±0.131

AUC0-∞ (µg.min/ml)

88.29±20.41

89.71±25.18

240.33± 29.59

t1/2 (min)

55.84±13.44

82.36±22.54

124.12±25.99
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Figure 3-4 represents the concentration-time profile of 8-methoxypsoralen in plasma and dermal
ECF (determined by ETS and cutaneous microdialysis) following oral administration of 5 mg/kg
of 8-methoxypsoralen. The pharmacokinetic parametes calculated from non-compartmental
analysis are given in Table 3-2.
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Figure 3-4. Time course of 8-methoxypsoralen in rat plasma (●-total drug; ♦-unbound drug)
determined by blood sampling and dermal ECF determined by microdialysis (■) and ETS (▲)
technique following oral administration of 5 mg/kg of 8-methoxypsoralen.

The Cmax and Tmax following oral administration of 5 mg/kg of 8-methoxypsoralen to hairless
rats was found to be 0.64±0.14 µg/ml and 120 min respectively, which is comparable to that
reported by Roelandts et al. Roelandts et al. have reported that following oral adminstration of 10
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mg/kg of 8-methoxypsoralen to rats, Cmax and Tmax were ~1.2 µg/ml and 150 min respectively
(112).
Table 3-2. Mean pharmacokinetic parameters of 8-methoxypsoralen (unbound) in plasma and
dermal ECF (determined by ETS and microdialysis) following oral administration of 5 mg/kg in
hairless rats.
Parameter

ETS

Microdialysis

Plasma

Tmax (min)

120

120

120

Cmax (µg/ml)

0.338 ± 0.080

0.280 ± 0.051

0.644 ± 0.142

AUC0-∞ (µg.min/ml)

116.08 ± 29.22

116.10 ± 22.85

120.72 ± 36.25

t1/2 (min)

243.83 ± 18.43

237.76 ± 15.83

97.15 ± 6.72

The point to point comparison of the drug concentration in the dermal ECF and the
dermatokinetic parameters, i.e. Cmax, Tmax, AUC0-∞ and t1/2 determined by ETS and microdialysis
technique for ciprofloxacin and 8-methoxypsoralen did not differ significantly (t-test, P<0.05)
(Table 3-1 and Table 3-2). This provides validity to the ETS technique for sampling drugs like
ciprofloxacin and 8-methoxypsoralen. The study also demonstrates that ETS could be
implemented in dermatokinetic investigation regardless of route of administration of drugs.
Successful development of a sampling device based on the ETS concept would be very useful in
carrying out dermatokinetic investigations of drugs. The noninvasiveness of the technique
permits frequent sampling of drugs which helps in relatively more precise calculation of the
kinetic parameters. In addition, the technique could be used to sample drugs in routine
therapeutic drug monitoring. ETS is a potential technique for cutaneous sampling of drugs and
analytes and could replace the invasive blood sampling procedure in future.
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3.5. CONCLUSIONS
The results of this project showed the workability of ETS in case of drugs with different
solubility and different degree of protein binding. In addition, the present work also demonstrates
the workability of the ETS technique in case of intravenous and oral routes of drug
administration.
Acknowledgements
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CHAPTER-4
NONINVASIVE TRANSCUTANEOUS SAMPLING OF GLUCOSE BY
ELECTROPORATION
4.1. ABSTRACT
Monitoring of blood glucose levels involves the invasive method of withdrawing blood
which causes inconvenience to patients. The objective of this study was to investigate the
efficiency of the noninvasive electroporation and transcutaneous sampling (ETS) technique for
predicting blood glucose levels. In vitro studies were carried out in Franz diffusion cells using
porcine epidermis to assess the feasibility of transcutaneous sampling of glucose. In vivo, the
ETS technique was assessed in the diabetes-induced Sprague-Dawley rat model. Glucose was
sampled following the application of 30 electrical pulses of 1 ms duration at 120 V/cm2, 1 Hz.
Clarke error grid analysis was carried out for the venous blood glucose levels that were
determined by the ETS with reference to those measured by a glucose meter. The amount of
glucose sampled by the ETS method both in vitro and in vivo was proportional to the dermal
glucose concentration. All data points from in vivo studies were in A and B zones of Clarke error
grid analysis, and the mean absolute relative error was 12.8%. Results of the present study
demonstrate that ETS technique could be developed as a noninvasive method of predicting
venous blood glucose levels in people with diabetes.
Keywords: Electroporation and transcutaneous sampling; Glucose; In vitro; In vivo
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4.2. OBJECTIVES AND SIGNIFICANCE
The objective of the study was to investigate the feasibility of utilizing ETS technique to
sample glucose from dermal ECF that correlates with blood glucose levels.
Diabetes mellitus is a major health concern. Diabetes can lead to chronic complications such as
heart disease, blindness, renal failure, peripheral vascular disease, and limb amputation (113,
114). For proper diabetes management, it is very important that blood glucose levels are checked
regularly. This involves the invasive method of collecting blood through a finger stick system
which has been a major inconvenience for patients (115). Some patients avoid glucose
measurements due to needle phobia. To overcome this problem, different noninvasive blood
glucose monitoring methods have been developed, including near-infrared spectroscopy, farinfrared spectroscopy, radio wave impedance, reverse iontophoresis, ultrasound, blister
technique, and microneedles (116-120). ETS technique involves application of a few short
electrical pulses on the surface of the skin, which permeabilize the stratum corneum by creating
transient aqueous pathways. The dermal glucose diffuses into the sampling fluid, which is in
contact with the permeabilized region of the skin.
4.3. MATERIALS AND METHODS
4.3.1. Chemicals
Glucose, alloxan monohydrate, and the glucose assay kit (GAHK-20) were purchased
from Sigma-Aldrich Inc. (St. Louis, MO); 10X phosphate-buffered saline (PBS) premixed
powder was obtained from EMD Chemicals (Gibbstown, NJ).
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4.3.2. Skin
Porcine belly skin was obtained from a local abattoir. Pieces of skin wrapped in
aluminum foil were heated to 60 °C for 2 min, and the epidermis was gently peeled off the skin.
The fresh epidermis was used for in vitro glucose sampling by electroporation.
4.3.3. In vitro glucose sampling by electroporation
In vitro diffusion studies were carried out in Franz diffusion cells (Logan Instruments
Ltd., Somerset, NJ) using porcine epidermis. The stratum corneum side of the skin was in
contact with the upper sampling compartment and the ventral side with the reservoir
compartment. The active diffusion area was 0.64 cm2. Ag/AgCl electrode wires of 0.5 mm
diameter (Alfa Aesar, Ward Hill, MA) made in the form of circular ring were placed 2 mm away
from the skin in both the sampling and the reservoir compartments. The upper sampling
compartment and the reservoir compartment were filled with 0.4 and 5 ml PBS respectively. The
electrical resistance of the epidermis was measured by placing a load resistor RL (100 kΩ) in
series with the epidermis. Voltage drop across the whole circuit (VO) and across the epidermis
(VS) were measured using a multimeter (Agilent Technologies, Santa Clara, CA). The piece of
porcine epidermis with a resistance greater than 20 kΩ.cm2 was used for the experiment.
The upper sampling compartment was filled with 0.4 ml of PBS, pH 7.4, and the lower reservoir
compartment was filled with 5 ml of glucose solution in PBS with concentrations between 50
and 400 mg/dl. Electroporation was carried out using an ECM 830 Electro Square Porator (BTX
Harvard Apparatus, Holliston, MA). The electroporation protocol was 30 pulses each of 1 ms
duration at 120 V/cm2 of active diffusion area. PBS from the sampling compartment was
withdrawn 15 min after the application of electrical pulses, and the amount of glucose was
measured using the glucose assay kit by UV spectrophotometer at 340 nm. The in vitro
permeability coefficient, Pin vitro (cm/min) was calculated using the formula:
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Pin vitro =

Glucose flux in 15 min
Glucose concentration in reservoir compartment

(7)

4.3.4. In vivo glucose sampling by electroporation
The in vivo experimental procedures were approved by the Institutional Animal Care and
Use Committee at the University of Mississippi (Protocol #07-028). In vivo studies were carried
out in Sprague-Dawley rats (Harlan, Indianapolis, IN) (200–224 g) under ketamine (80 mg/kg)
and xylazine (10 mg/kg) anesthesia. The moisture content in the epidermal layers and in the
dermis of each rat was measured using the Delfin moisture meter-SC and the Delfin moisture
meter-D (Delfin Technologies Ltd., Kuopio, Finland) before sampling to ensure the absence of
edema or inflammation (121).
Glucose sampling by ETS was carried out using a custom made sampling cell. The back portion
of rats was shaved, and a custom-made in vivo electroporation cell was fixed using an adhesive
(Krazy Glue, Elmers Products Inc., Columbus, OH). The cell contains a sample collection
chamber in which one of the Ag/AgCl electrodes was placed and the other electrode, which acts
as a counter electrode, was fixed just adjacent to the cell on the surface of the skin using
micropore surgical tape (3M Healthcare, St. Paul, MN). The skin was hydrated with 100 µl of
saline for 5 minutes before each sampling and was replaced with 400 µl of sampling buffer.
Thirty square electrical pulses each of 1 ms duration at 120 V/cm2 were applied, and the
sampling fluid remained in the chamber for 15 min after pulsing. The sampling fluid was
withdrawn, and the amount of glucose present was measured using the glucose assay kit (the
limits of detection were 0.1-5 mg/dl).
4.3.4.1. In vivo transcutaneous permeability coefficient
The calibration used to convert sampling chamber glucose to venous equivalent values is
nothing but determination of the permeability coefficient in rats having steady normal glucose
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levels. Constant venous glucose levels were confirmed by triplicate samples. Venous glucose
levels and corresponding ETS glucose levels of 18 data points in normal rats were used for
calibration. The normal venous glucose range in Sprague-Dawley rats is ~150-180 mg/dl (122).
The in vivo permeability coefficient, Pin

vivo

(cm/min), of rat skin was calculated using the

formula:
Pin vivo =

Glucose flux in 15 min
Venous blood glucose concentration

(8)

4.3.4.2. Sampling in diabetes-induced rats
Nine rats were used, of which three were in the control group and six were in the test
group. Transcutaneous sampling of glucose by ETS was carried out in the test group only. In the
control group, transcutaneous sampling was carried out without the application of electrical
pulses. All nine rats were injected with alloxan (200 mg/kg in saline) intraperitoneally. Generally
the duration required to induce irreversible diabetes with alloxan is ~24 h (123). Blood and
transcutaneous samples were obtained in all rats before injecting alloxan and also after 24 and 36
h after the injection of alloxan. The venous blood glucose was measured using a glucose meter
(True Track Smart System). From the ETS glucose levels, venous blood glucose concentrations
are predicted using the formula:

Venous blood glucose concentration=

Glucose flux in 15 min
Pin vivo

(9)

4.3.5. Data Analysis
The clinical utility of the method was determined based on the plot of data on a Clarke
error grid and determining the percentage of points located in the clinically acceptable A and B
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zones. Mean absolute relative error was also calculated to estimate the clinical accuracy using
the formula
% Mean absolute relative error= ቂ

൫Venous glucose-Venous glucose predicted from ETS൯
ሺVenous glucoseሻ

ቃ X 100

(10)

4.4. RESULTS AND DISCUSSION
Blood glucose is in homoeostasis with the peripheral tissue extracellular fluid. Therefore,
any change in the blood glucose is reflected in glucose levels in the tissue extracellular fluid. The
transdermal permeability of a polar diffusant such as glucose is limited because of the barrier
properties of stratum corneum. Therefore, transcutaneous sampling of glucose requires a
technique that can reversibly permeabilize the stratum corneum and facilitate the rapid diffusion
of glucose from dermal ECF into the sampling fluid. In vitro diffusion studies were carried out
across the porcine epidermis to assess the feasibility of ETS for sampling glucose. Sampling
without the application of electrical pulses (control) was not possible, as the glucose transfer by
passive diffusion was below detectable levels, whereas a significant amount of glucose diffused
following electroporation of the porcine epidermis. The electrical resistance of the epidermis
dropped by an average of 70±6% by the application of electrical pulses, indicating
permeabilization of the skin. In vitro ETS data are represented in Figure 4-1. Along with other
factors, the rate of diffusion is governed predominantly by the concentration of glucose in the
dermal extracellular fluid (presuming that the concentration of glucose in the sampling
compartment is negligible compared to the total glucose concentration in the reservoir
compartment). Therefore, the amount of glucose sampled by ETS was proportional to the
concentration of glucose in the reservoir compartment fluid (R2=0.93). The in vitro permeability
coefficient (Pin

vitro)

of porcine epidermis permeabilized by electroporation was 1.9±0.3×10-4

cm/min.
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Figure 4-1. Relationship between glucose concentration in the reservoir compartment and
glucose sampled by ETS across porcine epidermis in vitro.

Preclinical studies were carried out in a diabetes-induced Sprague-Dawley rat model to assess
the workability of the technique in vivo. The moisture content in the rat skin was measured to
ensure that there was no edema/inflammation in the region of glucose sampling. The
measurement also confirms the uniformity of degree of hydration of epidermal layers of skin.
The Delfin moisture meters measure the skin moisture contents in terms of dielectric constant of
the skin. The average dielectric constant values from moisture meters SC and D were 9.94±1.65
and 20.67±3.31, respectively. The in vivo permeability coefficient (Pin vivo) of rat skin for glucose
was found to be 1.95±0.15×10-5 cm/min. Again, a good linear correlation between the venous
glucose levels and the amount of glucose sampled by ETS was observed (R2=0.87).
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Generally, Clarke error grid analysis was performed to assess the clinical utility of glucose
monitoring devices. The analysis divides the reference and measured glucose into five zones-A,
B, C, D, and E. Values in zones A and B are considered clinically acceptable, whereas values in
zones C, D, and E lead to significant errors. At this stage we do not know if one can translate
results from rat model experiments to human application. However, assessing preclinical data
from a clinical perspective would provide some insight into the clinical applicability of the
technique. The venous blood glucose determined by blood sampling (x axis) (reference values)
and that predicted by the ETS techniques (y axis) are shown in Figure 4-2. All data points were
within Clarke error grid A and B zones. A mean absolute relative error of 12.8% was found for
all measurements (n=18) from in vivo data.
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Figure 4-2. Clarke error grid analysis of venous blood glucose (reference) and venous blood
glucose predicted by ETS in Sprague-Dawley rats.

4.5. CONCLUSIONS
Results support our hypothesis that the concentration of glucose sampled by ETS would
be proportional to the concentration of glucose in the dermal extracellular fluid. ETS could be
developed as a noninvasive method of monitoring blood glucose in people with diabetes.
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CHAPTER-5
“CHILDRIVE”: A TECHNIQUE OF COMBINING REGIONAL CUTANEOUS
HYPOTHERMIA WITH IONTOPHORESIS FOR THE DELIVERY OF DRUGS TO
SYNOVIAL FLUID

5.1. ABSTRACT
Bioavailability of drugs in the synovial fluid when administered via transdermal route is
highly limited due to the dermal clearance. The purpose of this project was to assess the
efficiency of ChilDrive (CD) technique to improve the drug targeting to the synovial fluid. CD is
a technique of transdermal delivery of drugs combining regional hypothermia and iontophoresis.
Diclofenac sodium and prednisolone sodium phosphate were administered by transdermal route
(Passive, Iontophoresis, Chil-Passive and ChilDrive) at the knee-joint region of hind limb in
Sprague-Dawley rats for 6 h. Intraarticular microdialysis was carried out to determine the time
course of drug concentration in the synovial fluid. Drug levels in synovial fluid after intravenous
and intraarticular administration were also determined. Iontophoretic delivery increased the
AUC0-t (area under the curve) of drugs in the synovial fluid by 3-fold over passive delivery
(0.86±0.04 and 2.0±0.06 µg.h/ml for diclofenac sodium and prednisolone sodium phosphate
respectively). CD resulted in an AUC0-t of 5.2±0.69 and 24.6±1.97 µg.h/ml for diclofenac
sodium

and

prednisolone

sodium

phosphate
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which

was

~6-12-fold

higher than passive and 2-4-fold higher than iontophoresis. The results support our hypothesis
that CD improves bioavailability of drugs to the synovial joints. CD could be developed as a
potential noninvasive technique for treatment of arthritis.
Keywords: Intraarticular microdialysis; Iontophoresis; Synovial fluid; Transdermal
5.2. OBJECTIVES AND SIGNIFICANCE
The objective of the study was:
I.

To assess the effect of iontophoresis combined with regional hypothermia (ChilDrive) for
enhancing the bioavailability of drugs in the synovial fluid.

The different types of joints present in the human body are classified into synovial, cartilaginous
and fibrous joints based on the degree and type of movement. Synovial joints are the most freely
moveable joints present in the knee, elbow, shoulder, hip, wrist and neck region of the human
body (124). The presence of lubricating synovial fluid differentiates synovial joints from
cartilaginous and fibrous joints. Arthritis is the most prevalent disorder affecting synovial joints
and a major cause of disability among people of all ages. During arthritis, the synovial fluid
secretion is affected due to the damage caused to the synovial membrane either due to body’s
own immune cells or due to break down of articular cartilage. This leads to thickening of the
synovial membrane, eventually resulting in swollen joints and decreased movement between
bones of the synovial joints. The major types of arthritis include rheumatoid arthritis,
osteoarthritis, juvenile rheumatoid arthritis and infectious arthritis. Pain and inflammation are
associated with arthritis (125). The most common treatment modalities for arthritic conditions
involve oral NSAIDs, including cyclooxygenase (COX) 2 inhibitors and intraarticular injection
of steroids. NSAIDs act by inhibiting the COX enzymes which are responsible for the
conversion of arachidonic acid into prostaglandins, which is a major cause of inflammation
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(126). Corticosteroids suppress the inflammatory parameters, like erythrocyte sedimentation rate
and C-reactive protein, resulting in decreased disease activity (127). Unfortunately, most of the
drugs are known to cause severe gastric irritation and other gastrointestinal disturbances
following oral administration. In addition, the systemic side effects are unavoidable due to
distribution of drugs (128, 129). Moreover, the amount of drug reaching the synovial joint would
be only a small fraction of the total administered dose. Although intraarticular injections provide
maximum bioavailability in the synovial cavity, they are invasive in nature and therefore do not
allow frequent administration (130). Harvey and Hunter suggested that the number of injections
in a single joint should not be more than four in a single year (131).
The synovial fluid present in joints is an ultrafiltrate of plasma which is continuously absorbed
and replenished by synovial lining of joint cavity, with a rapid turnover time of ~2 h (132, 133).
This is one of the main constraints in the treatment of arthritis as it results in rapid clearance of
drug from the synovial cavity. This necessitates either frequent administration or continuous
infusion of drugs into the synovial fluid to maintain effective level of drugs through the course of
treatment. In an infusion-type drug delivery system, a steady state drug level could be maintained
over prolonged durations. However, intraarticular infusion is practically not feasible unless the
patient is hospitalized and bedridden.
Transdermal delivery of drugs is noninvasive and is associated with advantages such as steady
state input of drugs, prolonged therapeutic activity, and minimized gastrointestinal and systemic
side effects. However, passive delivery of drugs through skin is not capable of achieving
required drug levels in the subdermal musculoskeletal tissues mainly due to the fact that the
majority of the drug that penetrates into skin will be cleared by the dermal circulation (134, 135).
One of the approaches to enhance deeper penetration of drugs is likely to increase the rate of
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drug delivery higher than the rate of dermal clearance (dQ/dt>Rcl) (Figure 5-1). The rate of drug
delivery is known to increase when iontophoresis is applied across the skin due to the repulsive
driving force on the drug ions. However, the rate of drug delivery by iontophoresis across skin is
limited by the maximum current density that can be applied. The maximum current that is
tolerable and safe is in the range of 0.4-0.5 mA/cm2 (136, 137).

Figure 5-1. Skin and subdermal tissues. dQ/dt represents rate of drug permeation across skin and
Rcl represents rate of dermal clearance of drug. The amount of drug reaching the subdermal
tissues could be increased by rendering Rcl<dQ/dt.

The second approach would be to reduce the rate of dermal clearance in order to accumulate
drug in the dermal tissue. Some research groups have attempted to enhance the delivery of drugs
to subdermal tissues by reducing the rate of dermal clearance with the help of vasoconstrictors
(138). Vasoconstrictors constrict the blood vessels and there-by reduce the blood perfusion rate
(thus the drug clearance) in the tissue. Higaki et al. have shown that there was ~3.3-9.6-fold
enhancement in the amount of antipyrine, salicylic acid, and diclofenac reaching muscle
followed by reducing blood flow upon topical administration of vasoconstrictor phenylephrine
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(139). But the use of vasoconstrictors over long durations is likely to cause severe undesirable
systemic and cardiovascular effects. Therefore, use of a biophysical technique that reduces the
regional blood perfusion would be safer than the vasoactive drugs.
Vuksanovic and coworkers studied the effect of temperature on the regional blood flow in skin
and have shown that when the skin temperature is >31 °C, the blood flow in the skin remains
constant. However, a rapid decrease in blood flow can be seen when skin temperature drops <31
°C due to vasoconstriction (140). Unlike the vasoactive drugs, temperature induced
vasoconstriction is a regional effect and hence regarded as relatively safe.
Diclofenac sodium and prednisolone sodium phosphate were selected as model drugs to assess
our hypothesis that regional hypothermia during iontophoretic transdermal delivery at the joints
leads to increased bioavailability of drugs in the synovial fluid.
5.3. MATERIALS AND METHODS
5.3.1. Chemicals
Diclofenac Sodium, Prednisolone Sodium Phosphate were procured from Sigma-Aldrich
Inc (St. Louis, MO), Phosphate buffered saline (PBS, pH 7.4) premixed powder was obtained
from EMD Chemicals (Gibbstown, NJ) and all other chemicals were obtained from Fischer
scientific (Fairway, NJ).
5.3.2. Animals
All the experimental studies were performed on 24 male Sprague-Dawley rats (200-250g)
under ketamine (80 mg/kg) and xylazine (10 mg/kg) anesthesia administered intraperitoneally.
The rats were procured from Harlan (Indianapolis, IN) and maintained on a 12-12 h light/dark
cycle in an animal facility with unlimited access to food and water. The animal studies were
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approved by the Institutional Animal Care and Use Committee (IACUC) at the University of
Mississippi (Protocol#09-006).
5.3.3. Intraarticular microdialysis
Intraarticular microdialysis was carried out to determine the amount of drug present in
the synovial fluid. After anaesthetizing the rats, the hind limb was held in a fixed position and an
introducer needle with split tubing was passed through the knee joint capsule, the needle was
removed and a CMA 20 microdialysis probe of 4 mm length and 20 kDa molecular weight cut
off (CMA, North Chlemsford, MA) was inserted through the split tubing. The split tubing was
withdrawn leaving the probe implanted in the synovial cavity. The implantation of probe in the
synovial cavity of rat is shown in Figure 5-2. PBS was perfused for 30 min prior to drug
administration for equilibration at flow rate of 2 µl/min. The probe recovery was determined in
vivo by using retrodialysis method. The proper placement of the probe in the synovial cavity was
confirmed by making an incision at the site of probe implantation after completion of studies.

Figure 5-2. Microdialysis probe implanted in the knee-joint for carrying out synovial fluid
microdialysis in hind limb of rat.
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5.3.4. Intravenous and intraarticular delivery of drugs
Diclofenac sodium and prednisolone sodium phosphate were given by intravenous route
through the tail vein (4 mg/kg) and intraarticular microdialysis was carried out for 6 h to
determine the time course of drug reaching the synovial fluid. Also, drug solutions were injected
directly into the synovial cavity (50 µl) in separate set of rats and intraarticular microdialysis was
carried out for 6 h.
5.3.5. Transdermal drug delivery
5.3.5.1. Design of iontophoretic patch
The iontophoretic patch (Figure 5-3) was fabricated using a woven adhesive backing
membrane fitted with a snap type Ag/AgCl electrode. One cm2 foam pad was attached onto the
backing membrane above the electrode. Drug solution (1%) made in PBS was filled in the foam
pad just before the application of patch. Similar patch was made which was filled with PBS and
acts as counter electrode.
The patch containing drug solution was placed on the lateral side of the rat knee and the counter
electrode was placed on the opposite side for all the transdermal drug delivery studies.
Intraarticular microdialysis was carried out for 6 h and the dialysate was collected every hour to
determine the amount of drug reaching the synovial fluid. In all the cases, drug containing patch
was applied only after the equilibration of microdialysis probe in the synovial joint.

58

Figure 5-3. Design of iontophoretic patch with ‘A’ displaying the dorsal view and ‘B’ displaying
the ventral view.

5.3.5.2 Passive drug delivery
Passive drug delivery studies were carried out for both the drugs by using the patches
fabricated with electrodes to maintain similar experimental conditions compared to
iontophoresis. In passive drug delivery, no current was applied.
5.3.5.3 Iontophoretic drug delivery
Iontophoresis was carried out using an IOMED Phoresor (Iomed Inc, Salt Lake city, UT)
by connecting the lead clips from the iontophoresis unit to the snap on the drug electrode and
counter electrode. Electrical current of 0.5 mA/cm2 was applied continuously for 6 h.
5.3.5.4. Chil-Passive drug delivery
Passive drug delivery carried out under regional hypothermia was termed as “chilpassive” drug delivery. Regional hypothermia was induced by placing the hind limb of the rats
on a water pad circulated continuously with water at reduced temperature (15-20 ○C) for the
entire period of study.
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5.3.5.5. ChilDrive (CD) drug delivery
Iontophoresis carried out under regional hypothermia was termed as “ChilDrive” (CD).
Regional hypothermia was induced according to method mentioned earlier. With exception of
regional hypothermia, all other experimental conditions were similar to iontophoretic drug
delivery.
5.3.6. Analytical methods
The amount of diclofenac sodium and prednisolone sodium phosphate present in
microdialysis samples was analyzed by high performance liquid chromatography. The HPLC
system (Waters, MA) consisted of a chromatographic pump (Waters 1525), an autosampler
(Waters 717 plus), a UV detector (Waters 2487) and a Symmetry® C18 column (4.6 x 150 mm).
Analysis of diclofenac sodium samples was carried out at a wavelength of 278 nm and the
mobile phase consisted of a mixture of acetonitrile and 0.01 M potassium dihydrogen phosphate
(pH 6.3), (35:65 v/v) with flow rate of 1 ml/min (141). The linearity range was between 10-1000
ng/ml (R2=0.99).
Analysis of prednisolone sodium phosphate samples was carried out at a wavelength of 242 nm
and the mobile phase was prepared by mixing 250 ml of isopropanol with 2 ml H3PO4 and
diluting with water to 900 ml. The pH of the solvent was adjusted to 3.0 with 1.0 M NaOH and
then diluted to 1000 ml with water and the flow rate was set to 1 ml/min (142). The linearity
range was between 10-1000 ng/ml (R2=0.99).
5.3.7. Statistical analysis
The statistical analysis of AUC0-t data after transdermal, intravenous and intraarticular
administration were determined by performing Unpaired t-test (GraphPad, InStat 3.0) to
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determine the level of significance between two groups. P<0.05 was considered as the level of
significance.
5.4. RESULTS AND DISCUSSION
Microdialysis technique was employed as a tool to investigate the time course of drug
concentration in the synovial fluid (79, 143). The in vivo probe recovery was performed using
retrodialysis method and was found to be 19.28±4.99% for diclofenac sodium and 23.01±5.48%
for prednisolone sodium phosphate.
5.4.1. Intravenous and intraarticular delivery of drugs
Drugs were administered intravenously to determine the fraction of the total dose
reaching the synovial fluid. The time course of drug in the synovial fluid upon intravenous
administration is shown in Figure 5-4 and 5-5.
The AUC0-t in the synovial fluid after intravenous administration was found to be 0.609±0.02
µg.h/ml for diclofenac and 1.445±0.17 µg.h/ml for prednisolone. The total AUC0-t in the
synovial fluid by systemic administration was comparable with that of passive topical delivery of
drugs (Table 5-1 and 5-2) and was significantly less than all the other modes of drug
administration. From these results it appears that the systemic delivery of drug for treating
synovial disorders may not end in remarkable results unless the dose and frequency are high
enough to maintain effective drug levels over long duration.
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Figure 5-4. Time course of diclofenac sodium in synovial fluid upon intraarticular (●) and
intravenous (■) administration.

The Cmax and Tmax in synovial fluid for diclofenac following intravenous administration were
0.174 µg/ml and 4 h. Similarly for prednisolone sodium phosphate they were found to be 0.339
µg/ml and 2 h. Obviously, delivery of drugs directly into the synovial cavity resulted in
significantly higher bioavailability than all the other modes of drug administration (Table 5-1
and 5-2). The concentration-time profile followed a mono-exponential disposition curve (Figure
5-4 and 5-5).
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Figure 5-5. Time course of prednisolone sodium phosphate in synovial fluid upon intraarticular
(●) and intravenous (■) administration.
Table 5-1. AUC0-t and Cmax of diclofenac sodium in synovial fluid following transdermal
(Passive, Chil-Passive, Iontophoresis, ChilDrive), intravenous and intraarticular administration.

AUC0-t (µg.h/ml)

Cmax (µg/ml)

Passive

0.864 ± 0.042

0.188 ± 0.022

Chil-Passive

1.336 ± 0.105

0.287 ± 0.024

Iontophoresis

2.683 ± 0.152

0.644 ± 0.036

ChilDrive

5.208 ± 0.693

1.259 ± 0.098

Intravenous

0.609 ± 0.028

0.174 ± 0.009

Intraarticular

77.829 ± 5.422

25.974 ± 1.340
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Table 5-2. AUC0-t and Cmax of prednisolone sodium phosphate in synovial fluid following
transdermal (Passive, Chil-Passive, Iontophoresis, ChilDrive), intravenous and intraarticular
administration.

AUC0-t (µg.h/ml)

Cmax (µg/ml)

Passive

2.003 ± 0.067

0.468 ± 0.106

Chil-Passive

3.958 ± 0.303

0.863 ± 0.055

Iontophoresis

6.364 ± 0.486

1.724 ± 0.423

ChilDrive

24.605 ± 1.975

7.360 ± 1.032

Intravenous

1.445 ± 0.174

0.339 ± 0.032

Intraarticular

479.946 ± 45.040

141.890 ± 20.179

The AUC0-t in synovial fluid after intraarticular administration was 77.82±5.42 and
479.94±45.04 µg.h/ml for diclofenac sodium and prednisolone sodium phosphate respectively.
However, one should note that the drugs administered into the synovial cavity were eliminated
rapidly as reflected by the elimination half-lives of drugs in the synovial fluid (t1/2 was 1.55±0.02
h for diclofenac and 1.19±0.01 h for prednisolone respectively). The rapid elimination of drug
could be attributed to the rapid turnover of synovial fluid and/or to the metabolism of drug in the
synovial fluid. Relatively longer half-life of diclofenac in the synovial fluid is likely due to
slightly higher protein binding (>98%) compared to prednisolone (65-91%) (144, 145).
5.4.2. Passive drug delivery
Vuksanovic et al. have clearly demonstrated using the laser doppler studies that the blood
perfusion rate in the skin tissue is decreased under hypothermic conditions (140). The decreased
blood flow is likely to result in decreased rate of dermal clearance of drugs. Passive drug
delivery studies were carried out at normal body temperature and at regional hypothermia
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condition (Chil-Passive) for both the drugs. The drug concentration-time profile in the synovial
fluid was used to calculate the AUC0-t. The total AUC0-t in synovial fluid after passive
transdermal administration of drugs was almost doubled due to induction of regional
hypothermia (Table 5-1 and 5-2).
5.4.3. Iontophoretic drug delivery
Application of iontophoresis (0.5 mA/cm2) resulted in enhanced bioavailability of drugs
into the synovial cavity (Figure 5-6 and 5-7). Iontophoresis mediated delivery of drugs resulted
in 3-fold (P<0.01) higher AUC0-t in synovial fluid compared to passive drug delivery (Table 5-1
and 5-2). These results are in agreement with previous reports in which other authors showed
that iontophoresis aids in better treatment of joint disorders. Aiyejusunle et al. have reported that
cathodal iontophoresis (0.1-0.3 mA/cm2) of sodium salicylate resulted in reduced pain and
functional disability. Bender et al. have shown that the concentration of etofenamate in the
synovial fluid following iontophoresis was twice that of etofenamate levels in serum and hence
topical iontophoresis of etofenamate was suitable for alleviation of arthritis in superficially
located joints (146, 147).
In case of CD, iontophoresis was carried out by placing hind limb portion of rat on a water pad
through which water at 20 ºC was circulated, so that temperature of skin was maintained in the
range of ~20-25 ºC throughout the study. Reducing skin temperature has been widely used in
treatment techniques like cryotherapy where-in temperatures in the range of 7-20 ○C have been
used. As hypothermia is induced regionally in the present studies, it is less likely to lead to any
physiological changes in the whole body. Chesterton et al. reported that physiological changes
like local analgesia, reduced nerve conduction velocity, and reduced metabolic enzyme activity
are seen only at temperatures below 14 ○C (148).
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Synovial fluid concentration of diclofenac sodium
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Figure 5-6. Time course of diclofenac sodium in the synovial fluid following different modes of
transdermal administration (♦-Passive, ■-Chil-Passive, ▲-Iontophoresis and ●-ChilDrive).

The AUC0-t of drug in the synovial fluid due to CD was ~2-4-fold (P<0.01) higher than
iontophoresis in case of both the drugs. This is exactly the fold of enhancement observed
between passive transdermal and chil-passive as well. Compared to passive drug delivery, the
AUC0-t in the synovial fluid of drugs when administered by CD was ~6-12-fold higher (P<0.01).
Interestingly, all the synovial concentration-time profiles following transdermal drug
administration showed a typical initial increase followed by decrease in drug concentration
regardless of the mode of drug delivery. It is likely that the change in the synovial fluid turnover
rate due to insertion of the probe might have caused this kind of concentration-time profile.
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Synovial fluid concentration of prednisolone
sodium phosphate (µg/ml)
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Figure 5-7. Time course of prednisolone sodium phosphate in the synovial fluid following
different modes of transdermal administration (♦-Passive, ■-Chil-Passive, ▲-Iontophoresis and
●-ChilDrive).
5.5. CONCLUSION
Regional hypothermia is one the most promising approaches to reduce the rate of clearance of
drug from the skin. ChilDrive can be developed as a potential way of treating musculoskeletal
disorders. The technology is likely to be more patient compliant than oral or parenteral delivery
of drugs.
“With kind permission from Springer Science+Business Media: Pharmaceutical Research,
“ChilDrive”: A technique of combining regional cutaneous hypothermia with iontophoresis for
delivery of drugs to synovial fluid, 26, 2009, 2535-2540, Srinivasa M. Sammeta and S.
Narasimha Murthy.”
67

CHAPTER-6
MAGNETOPHORESIS FOR ENHANCING TRANSDERMAL DRUG DELIVERY:
MECHANISTIC STUDIES AND PATCH DESIGN

6.1. ABSTRACT
Magnetophoresis is a method of enhancement of drug permeation across biological
barriers by the application of magnetic field. The present study investigated the mechanistic
aspects of magnetophoretic transdermal drug delivery and also assessed the feasibility of
designing a magnetophoretic transdermal patch system for the delivery of lidocaine. In vitro drug
permeation studies were carried out across the porcine epidermis at different magnetic field
strengths. The magnetophoretic drug permeation “flux enhancement factor” was found to
increase with the applied magnetic field strength. The mechanistic studies revealed that the
magnetic field applied in this study did not modulate permeability of the stratum corneum
barrier. The predominant mechanism responsible for magnetically mediated drug permeation
enhancement was found to be “magnetokinesis”. The octanol/water partition coefficient of drugs
was also found to increase when exposed to the magnetic field. A reservoir type transdermal
patch system with a magnetic backing was designed for in vivo studies. The dermal
bioavailability (AUC0-6h) from the magnetophoretic patch system in vivo in rats was significantly
higher than the similarly designed non-magnetophoretic control patch.
Keywords: Magnetophoresis; Transdermal; Lidocaine; Partition coefficient; Enhancer
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6.2. OBJECTIVES AND SIGNIFICANCE
The objectives of the study are:
I.

To investigate the technique of magnetophoresis for enhancing transdermal drug
permeation.

II.

To resolve the mechanisms leading to enhanced transdermal drug permeation by
magnetophoresis.

III.

To assess the feasibility of designing a simple magnetophoretic transdermal patch
system.

Transdermal permeation of polar and hydrophilic drugs is limited by the barrier property of
stratum corneum. Therefore, several chemical and physical permeation enhancement techniques
have been explored to improve the transdermal delivery of poorly permeable drugs (29, 149151). In this direction, Murthy et al. investigated the plausibility of using magnetic field to
enhance the transdermal permeation of drugs. The authors reported for the first time that the
static magnetic field could facilitate the transdermal permeation of drugs such as benzoic acid,
salbutamol sulfate and terbutaline sulfate (152, 153). The authors speculated that the enhanced
transdermal drug permeation by the applied magnetic field could be a combination of multiple
mechanisms such as magnetokinesis and alteration of barrier property of skin. A recent study by
Krishnan et al. utilized an electromagnetic field to enhance the drug permeation across the skin.
Krishnan et al. reported that the potential mechanism for enhanced transdermal drug permeation
by the electromagnetic field of 5 mT was due to modulation of the permeability of stratum
corneum (154). There are a number of reports regarding the use of magnetite incorporated
particulate systems in drug delivery and imaging. An externally applied magnetic field has been
shown to direct the systemically administered magnetoliposomes or nanoparticles to the target
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tissue (155, 156). The mechanism associated with this approach is attraction of the ferromagnetic
substance, magnetite, towards the magnetic field. The present project involved delivery of a drug
across the skin by application of magnetic field, where drug molecules which are diamagnetic in
nature are repelled away from the magnetic field. The base and salt form of a local anesthetic,
lidocaine which is a diamagnetic molecule was selected as the candidate for the present study.
6.3. MATERIALS AND METHODS
6.3.1. Materials
Lidocaine Hydrochloride (LH) was purchased from Spectrum Chemicals (New
Brunswick, NJ), lidocaine base (LB), D-mannitol and sodium chloride were procured from
Sigma-Aldrich Inc. (St. Louis, MO). [3H] Water and D-[1-14C] Mannitol were procured from
American Radiolabeled Chemicals, Inc. (St. Louis, MO) and all other chemicals were obtained
from Fischer Scientific (Fairway, NJ). Neodymium magnets were purchased from United
Nuclear Scientific (Laingsburg, MI) and K&J Magnetics, Inc. (Jamison, PA).
6.3.2. Porcine epidermis
Porcine belly skin was obtained from a local abattoir. Pieces of skin wrapped in
aluminum foil were heated to 60 ºC for 2 min and the epidermis was gently peeled off the skin.
The fresh epidermis was placed on glass microscopic slides and kept dry at 4 ºC and was used
within three days. Prior to use, the epidermis was hydrated with normal saline for an hour.
6.3.3. General in vitro experimental setup
A vertical Franz-type diffusion apparatus (PermeGear, Inc. Hellertown, PA) was used for
all resistance measurements and drug permeation studies across the porcine epidermis. A piece
of porcine epidermis was placed between the two compartments of the diffusion apparatus, one
serving as the donor and other as the receiver compartment. The active diffusion area of the
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epidermis was 0.2 cm2. The receiver compartment (5 ml) and donor compartment (0.2 ml) were
filled with isotonic saline solution. Ag/AgCl electrode wires of 0.5 mm diameter (Alfa Aesar,
Ward Hill, MA) made in the form of concentric rings were placed 2 mm away from the porcine
epidermis in both the donor and the receiver compartments. Before carrying out permeation
studies, the electrodes were connected to the electrical set up for resistance measurement. The
electrical resistance of the epidermis was measured and only pieces of epidermis, which had
resistances greater than 20 kΩ.cm2 were used for the experiments. During the in vitro drug
permeation studies the temperature of receiver compartment was maintained at 37±1 ○C by water
circulation.
6.3.4. Passive drug permeation studies
After the electrical resistance measurement, the isotonic saline in the donor compartment
was replaced with 0.2 ml of LH solution (10 mg/ml) or LB solution (1.66 mg/ml) prepared in
isotonic saline and the permeation studies were carried out for 8 h. During the course of
permeation studies, at each sampling time point (2, 3, 4, 5, 6, 7 and 8 h) 0.2 ml of the receiver
compartment solution was sampled out, and was subsequently replaced with fresh isotonic saline
solution. The amount of drug in the samples was analyzed by HPLC.
6.3.5. Magnetophoretic drug permeation studies
The experimental set up was similar to passive drug permeation studies, and
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magnetic field was applied by placing two neodymium magnets (1.2 cm length x 0.6 cm width x
0.6 cm thickness) on either side of the donor compartment and at a distance of 2 mm above the
porcine epidermis (Figure 6-1). Permeation studies were carried out for 8 h at different magnetic
field strengths of 30, 150 and 300 mT. The amount of drug permeated across porcine epidermis
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into the receiver compartment solution was determined by analyzing the samples withdrawn at
different time points as discussed in section 6.3.4.

Figure 6-1. Experimental set up for permeation studies. Porcine epidermis ‘A’ was sandwiched
between the donor compartment ‘B’ filled with drug solution and receiver compartment ‘C’
filled with isotonic saline. Two neodymium magnets ‘D’ were placed on either side of the donor
compartment. The donor and receiver compartments were fitted with Ag/AgCl electrode wires
for measurement of electrical resistance.
6.3.6. Drug permeation across the dialysis membrane
The drug permeation studies were carried out across Spectra/Por® dialysis membrane
(1000 Da molecular weight cut-off) in the absence and presence of magnetic field (300 mT)
following exactly the same procedure described in the passive and magnetophoretic drug
permeation studies (Section 6.3.4 and 6.3.5).
6.3.7. Drug permeation across the pretreated epidermis (epidermis exposed to magnetic
field)
The porcine epidermis was pretreated (for 24 h) by exposure to the magnetic field by
using a similar set up as shown in Figure 6-1, without placing any medium in the donor
compartment. After the pretreatment, the donor chamber was filled with drug solution and the

72

passive drug permeation studies were carried out across the pretreated epidermis similar to that
discussed in section 6.3.4.
6.3.8. [3H] Water and D-[1-14C] Mannitol transport studies
The experimental set up was similar to that used for the passive and magnetophoretic
drug permeation studies (Section 6.3.4 and 6.3.5). The donor compartment was filled with 0.2 ml
of [3H] water (20 µCi/ml) in isotonic saline for water transport studies. Mannitol (1 mg/ml) and
[1-14C] mannitol (5 µCi/ml) in isotonic saline was placed in the donor compartment for mannitol
transport studies. The receiver compartment was filled with isotonic saline in both the studies. In
the case of magnetophoretic permeation studies, a magnetic field of 300 mT was applied. After
the passive and magnetophoretic permeation studies, tritiated water and mannitol transport across
porcine epidermis was measured by withdrawing samples at regular intervals for a period of 8 h.
The amount of [3H] water and [14C] mannitol was determined by scintillation counting
(Scientisafe Econo 2 cocktail, Fischer Scientific, Fairway, NJ; liquid scintillation analyzer, TriCarb 1600 TR, Packard Bioscience, Meriden, CT).
6.3.9. Transepidermal Water Loss (TEWL) studies
The TEWL was measured using a Vapometer (Delfin Technologies, Kuopio, Finland).
Porcine epidermis was mounted between the receiver and donor compartments of the diffusion
cell (Figure 6-1). Isotonic saline solution was placed only in the receiver compartment and the
donor compartment was kept empty. The whole set up was placed in a temperature (37 °C) and
humidity (RH 55%) controlled chamber and the TEWL was measured by fixing the Vapometer
directly on the donor compartment. TEWL was measured prior to the start of the experiment.
The test set was exposed to magnetic field (300 mT). The TEWL was measured at different time
points up to 8 h.
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6.3.10. Fourier Transform Infrared (FT-IR) spectroscopic studies
The porcine epidermis was subjected to FT-IR spectroscopic studies in absence and
presence of magnetic field. Infrared spectra were obtained in the transmission mode using a
Nicolet 6700 FT-IR spectrometer in the frequency range 4000-1000 cm-1. Sixty four scans were
collected at 4 cm-1 resolution. The same piece of porcine epidermis was used for recording the
spectra in absence and presence of magnets. Two magnets were placed on the surface of porcine
epidermis at a distance of 6 mm with unlike poles facing each other (magnetic field of 300 mT)
for recording the spectra. The magnets used, distance between magnets and polarity were same
as those used for in vitro permeation studies.
6.3.11. Effect of magnetic field on octanol-water and stratum corneum (SC)-aqueous
vehicle partitioning of drug
To determine the octanol-water partition coefficient, deionized water equilibrated with an
equal volume of octanol was used to prepare the drug solution. 0.2 ml of drug solution
(concentrations of 50, 100, 250 and 500 µg/ml) was placed in contact with 0.2 ml of octanol in a
glass vial. The two phases were mixed thoroughly by vigorous shaking for 6 h and allowed to
equilibrate for next 18 h. After equilibration, 20 µl of aqueous and octanol phases were
withdrawn for measurement and calculation of “initial partition coefficient”. The vials from the
test group were placed in presence of magnetic field (300 mT) and the control set were not. Only
the aqueous phase was placed in presence of magnetic field. After 24 h, the “final partition
coefficient” of the drug in the control and test set of vials was determined. The average
difference in the partition coefficient (final partition coefficient value-initial partition coefficient
value) was compared between control and the test sets.
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To determine SC-vehicle partition coefficient, preweighed samples of SC (isolated by trypsin
digestion method as shown by Essa et al.) were placed in 0.2 ml of drug solution in isotonic
saline (100 µg/ml) in a glass vial for 48 h (157). A magnetic field of 300 mT was applied on the
bulk of the vehicle in the vial, only to the test group. At the end of 48 h, the amount of drug
present in the vehicle and SC were measured to estimate the partition coefficient of drug.
6.3.12. Fabrication of magnetophoretic transdermal patches
Magnetophoretic transdermal patches were designed by affixing a series of neodymium
magnets (10 mm length x 1.5 mm width x 1.5 mm thickness) on a nonmagnetic backing
membrane which is placed over an adhesive 3M™ foam tape (3M Drug Delivery Systems, St.
Paul, MN). About 200 mg of LH and LB gel (2% w/w) prepared in HPMC base (4% w/v) was
spread over the magnets (1.5 cm2) as a thin layer, which acts as drug reservoir. The magnetic
field strength at the skin surface of the magnetophoretic patch system was 450 mT. In the case of
passive transdermal patches, the neodymium magnets were replaced with similar nonmagnetic
metal pieces.
LH gel was prepared using HPMC in deionized water; whereas, LB gel was prepared using
HPMC in hydroalcoholic solution (water:alcohol, 70:30) due to the limited solubility of LB in
aqueous medium.
6.3.13. In vivo dermal bioavailability studies of magnetophoretic patch system
The animal studies were approved by the Institutional Animal Care and Use committee
(IACUC) at the University of Mississippi (Protocol#09-031). The in vivo studies were performed
on 12 male Sprague-Dawley rats (200-250 g) under ketamine (80 mg/kg) and xylazine (10
mg/kg) anesthesia administered intraperitoneally. The rats were procured from Harlan
(Indianapolis, IN).
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Cutaneous microdialysis was carried out in rats by inserting a 20G needle intradermally through
a distance of 2 cm and a linear microdialysis probe of 5 mm membrane length and 30 kDa cutoff molecular weight (BASi, West Lafayette, IN) was inserted through this needle and the needle
was withdrawn leaving the probe implanted in the dermal tissue. The inlet tube was connected to
an injection pump (BASi, West Lafayette) and isotonic saline solution was perfused at a flow
rate of 2 µl/min. After equilibration of the probe for 30 min, a transdermal patch system was
placed above the region where microdialysis probe was inserted and studies were carried out for
a period of 6 h. For both the salt (LH) and base (LB) forms of the drug, animal studies were
performed using passive and magnetophoretic patch systems respectively. The probe recovery
was determined in vivo by retrodialysis method.
6.3.14. Analytical method
The amount of lidocaine hydrochloride and lidocaine were analyzed by high performance
liquid chromatography. The HPLC system (Waters, MA) consisted of a chromatographic pump
(Waters 1525), autosampler (Waters 717 plus) and an UV absorbance detector (Waters 2487).
Symmetry® C18 column (4.6 x 150 mm) was used and the mobile phase consisted of a mixture
(14/86 v/v) of acetonitrile and potassium dihydrogen phosphate 0.05 M (pH adjusted to 4.0) 1.3
ml/min at 216 nm (158).
6.3.15. Statistical analysis
Statistical analysis was carried out using GraphPad InStat 3 software. Unpaired t-test was
performed and P<0.05 was considered as the level of significance.
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6.4. RESULTS AND DISCUSSION
Porcine epidermis has been accepted as one of the most appropriate models for
transdermal drug delivery studies due to its similarities in structure and lipid composition of
stratum corneum with the human (159-161). Therefore, porcine epidermis was employed in all
the in vitro experiments in the present study. The magnetic field of different strengths (30300 mT) was generated by varying the distance between the poles of bar magnets or by using
magnets of different strengths. The magnetic field strengths were measured at the surface of the
epidermis using a hand-held Gauss/Tesla meter (F.W. Bell, Model # 4048).
6.4.1. Magnetophoresis of LH across the porcine epidermis
The data from Figure 6-2 and Table 6-1 clearly demonstrate the ability of magnetic field
to enhance the permeation of LH across the porcine epidermis. The permeation flux
enhancement factor (EF) (Permeation flux in presence of magnetic field / flux in absence of
magnetic field) was found to increase linearly with increasing applied magnetic field strength as
shown in the insert graph in Figure 6-2. The relationship between the permeation flux
enhancement factor for LH and magnetic field strength could be presented as EF = 0.027S+1,
(R2=0.92) where ‘EF’ is the flux enhancement factor and ‘S’ is the strength of magnetic field at
the surface of the epidermis.
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Figure 6-2. Cumulative permation of LH across porcine epidermis in case of passive (♦),
magnetic field strength of 30 mT (■), 150 mT (▲) and 300 mT (●). Insert graph shows plot of
magnetic field strength vs. flux enhancement factor.
Table 6-1. Permeation flux and flux enhancement factor of LH and LB across porcine
epidermis.
LH
Magnetic
field (mT)

LB

Permeation flux
(µg/cm2/h)

Flux
enhancement
factor (EF)

Permeation
flux (µg/cm2/h)

Flux
enhancement
factor (EF)

0

0.18 ± 0.06

1.0

0.57 ± 0.12

1.0

30

0.53 ± 0.09

2.9

0.75 ± 0.18

1.3

150

1.01 ± 0.17

5.6

1.14 ± 0.29

2.0

300

1.61 ± 0.12

8.9

2.23 ± 0.22

3.9
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The concept of utilizing magnetic field for enhancement of transdermal drug delivery emanated
from the hypothesis that diamagnetic substances, which are generally repelled away from the
external magnetic field would be driven across the biological barrier along the direction of the
magnetic field gradient. However, the diamagnetic susceptibility is considered to be a very weak
property and the driving force generated under mT range magnetic field is regarded as rather
mild. Despite this, a significant transdermal permeation enhancement of drug was observed in
the presence of magnetic field suggesting that the magnetophoresis phenomenon could involve
multiple mechanisms.
Generally, transdermal physical permeation enhancement techniques are known to cause
enhanced drug permeation across the biological barriers by mechanisms such as kinesis of drug
molecules and/or by alteration of the biological barrier. Iontophoresis is one of the techniques
which is known to enhance the transdermal drug permeation predominantly by driving the drug
ions due to electrorepulsion. On the other hand, techniques such as electroporation, sonophoresis
and thermoporation enhance the transdermal delivery of drugs by disruption of the stratum
corneum barrier. To resolve the role of different mechanisms in case of magnetophoresis,
systematic mechanistic studies were carried out as discussed further in this study.
6.4.2. Permeation across the pretreated epidermis (epidermis exposed to magnetic field)
To assess the plausible effect of an applied magnetic field on the barrier property, the
epidermis was pretreated by exposure to magnetic field (30, 150 and 300 mT) for 24 h. Passive
permeation studies (in absence of magnetic field) were carried out across the pretreated
epidermis. Permeation experiments across the untreated epidermis served as control. The
permeation flux across the epidermis did not differ significantly between pretreated and
untreated epidermis suggesting that prior exposure of the epidermis to magnetic field did not
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bring about any long lasting change in the epidermal permeability (Table 6-2). However, this
experiment did not rule out the possibility of any potential real time microstructural changes in
the epidermis during the magnetophoretic drug permeation studies.
Table 6-2. Permeation flux of LH and LB across pretreated porcine epidermis (Epidermis
exposed to magnetic field for 24 h). The epidermis was exposed to different magnetic field
strengths and the drug permeation studies were carried out across the pretreated epidermis.

Pretreatment
Magnetic field (mT)

Permeation flux after pretreatment (µg/cm2/h)
LH

LB

0

0.17 ± 0.05

0.59 ± 0.09

30

0.18 ± 0.03

0.56 ± 0.13

150

0.16 ± 0.06

0.60 ± 0.19

300

0.17 ± 0.03

0.57 ± 0.16

TEWL and electrical resistance have been considered as two promising parameters used to
assess the barrier integrity of the stratum corneum (162, 163). However, TEWL is known to be
relatively less sensitive than electrical resistance as it can only reflect mechanical disruption of
the barrier. On the other hand, electrical resistance is relatively more sensitive and could change
significantly even due to any microstructural changes in the stratum corneum. TEWL and
electrical resistance of the porcine epidermis were measured at different time points while the
epidermis was being exposed to magnetic field. The initial TEWL and electrical resistance of the
porcine epidermis was 6.15±0.71 g/m2/h and 38.1±1.2 kΩ.cm2 respectively. The TEWL value
across the intact epidermis that has been reported by other groups agrees well with that found in
this case (164, 165). The TEWL and electrical resistance remained constant during study period
of 8 h. Therefore, it is most likely that, at the applied magnetic field strengths in these
experiments, no significant real time transient structural alterations occurred in the epidermis.
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To further confirm the non-interaction of the magnetic field with the stratum corneum lipids, the
epidermis were subjected to FT-IR studies. The FT-IR spectra of the stratum corneum side were
recorded before and after exposure to the magnetic field. A custom designed skin holder was
used to hold the magnets in place even while the spectra were recorded. There was no significant
shift in the peaks in the lipid region (2920 and 2850 cm-1) or in the amide regions (1650 and
1550 cm-1) as clearly seen in the representative spectra shown in Figure 6-3, even after exposure
to magnetic field for over 80 h. This data also supplements the hypothesis that the magnetic field
strength used in this project has negligible or no effect on the skin structure and permeability.

Figure 6-3. Representative FT-IR spectra of porcine epidermis in absence of magnetic field (A),
presence of magnetic field (B) and after exposure to magnetic field for 80 h (C).
6.4.3. Magnetokinesis of drug
Magnetokinesis is a phenomenon of forced propagation of drug molecules under the
applied magnetic field. Magnetokinesis of molecules and particles under a gradient magnetic
field has been reported in the past by several research groups (166, 167). There are at least two
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potential mechanisms that can contribute to magnetokinesis in the present experimental set up;
magnetorepulsion and magnetohydrokinesis. Magnetorepulsion could be described as driving of
the drug molecules (due to the repulsive force experienced by the induced diamagnet) in the
presence of external magnetic field. Magnetohydrokinesis mediated drug transport is due to the
movement of water across the membrane under the influence of an external magnetic field.
These mechanisms are comparable to electrorepulsion and electroosmosis in the case of
iontophoretic transdermal drug delivery. To reassess if magnetokinesis is one of the mechanisms
leading to transdermal drug permeation enhancement, permeability studies were also carried out
across the dialysis membrane with a cut-off size of 1000 Da. A nonbiological barrier like dialysis
membrane was chosen to eliminate any effect of magnetic field on the barrier. Interestingly,
application of magnetic field (300 mT) enhanced the permeation flux of LH across the dialysis
membrane also by ~ 4-fold over passive permeation (passive: 10.79±2.26 µg/cm2/h vs. magnet:
38.98±6.21 µg/cm2/h). These results suggest that magnetokinesis is one of the predominant
mechanisms responsible for drug permeation enhancement at these applied magnetic field
strengths. However, these experiments did not differentiate the relative contribution due to
magnetorepulsion and magnetohydrokinesis.
Magnetohydrokinesis across the epidermis under the influence of the applied magnetic field was
investigated by studying the transport of tritiated water across the epidermis. There was a
significant difference between the water transport flux across the epidermal membrane in the
absence (32.63±5.25 nl/cm2/h) and presence (57.21±8.63 nl/cm2/h) of magnetic field (300 mT)
indicating that hydrokinesis could be one of the factors contributing significantly to the overall
drug transport due to magnetokinesis.
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Enhanced transport of water would result in proportionately enhanced transport of dissolved
substances as well. Therefore to add supportive evidence to the magnetohydrokinesis
phenomenon, transport of 14C-mannitol across the epidermis was investigated. The application of
magnetic field (300 mT) resulted in ~2.7-fold enhancement (5.18±1.88 ng/cm2/h) in the transport
flux of mannitol as compared to passive diffusion (1.89±0.49 ng/cm2/h). The contribution of
magnetohydrokinesis to the drug transport across biological membranes may become more
apparent when higher magnetic field strengths are applied and may become remarkably
significant when a more concentrated drug solution is placed in the donor chamber.
6.4.4. Effect of magnetic field on octanol-water and SC-aqueous vehicle partitioning of
drug
One of the predominant factors known to determine the permeation of drugs across the
skin is the partition coefficient. Generally, chemical permeation enhancers improve the drug
permeation by increasing the partitioning of drug into the skin lipids. Sun et al. have shown that
induction of magnetic field enhanced the extraction of acetone due to the increase in partition
coefficient (168). In the present work, the effect of exposure to magnetic field on the partition
coefficient of drug between octanol and water phases was investigated. The partition coefficient
of LH in the absence of magnetic field was 13.80±4.79 and in the presence of magnetic field
(300 mT) was found to be 28.94±2.11. In the present set up for determination of partition
coefficient, the aqueous phase was exposed to the magnetic field and the gradient exists along
the aqueous→organic phase direction. It is likely that the drug molecules are driven to the
interface along the field gradient which in turn modulates the thermodynamic equilibrium in a
way that favors more partitioning of drug into the octanol phase. The other potential reason for
enhanced octanol partitioning of the drug could be due to the changes in the solvent properties
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due to exposure to the magnetic field. The SC-aqueous vehicle partition coefficient of LH was
also found to increase to 0.125±0.02 in presence of magnetic field compared to 0.037±0.012 in
absence of magnetic field.
6.4.5. Magnetophoresis of lidocaine base
LB has a better skin permeation property than its salt (LH) as it is relatively more
lipophilic than LH (log P of LB is 2.02 vs. 1.15 for LH under the present experimental
conditions). Even in case of LB, an increasing trend in the enhancement factor was observed
with increasing magnetic field strengths (Table 6-1) (EF= 0.009S+1). However, in general, at any
given magnetic field strength, the enhancement factor was higher in case of LH than LB. This
appears to be just because the passive permeation flux of LB was ~3-fold higher than that of LH
(Table 6-1).
Similar to LH, even in the case of LB, there was no enhancement in permeation flux across the
porcine epidermis pretreated by exposure to the magnetic field (Table 6-2). When permeation
studies of LB were performed across the dialysis membrane, an enhancement of ~3-fold was
observed in the presence of magnetic field (300mT) (passive: 4.95±1.99 µg/cm2/h vs. magnet:
14.47±3.06 µg/cm2/h).
The octanol-water partition coefficient of LB was 103.61±4.06 and it was increased to
128.55±3.91 in presence of magnetic field (300 mT). The SC-aqueous vehicle partition
coefficient of LB in the presence of the magnetic field (0.171±0.03) was increased when
compared to that in the absence of magnetic field (0.092±0.01). As compared to the ~110%
increase in the partition coefficient of LH, the increase in the case of LB was significantly less
(~24%). Comparable to this, the increase in partition coefficient between SC-vehicle was
enhanced by ~237% in the case of LH as compared to ~85% in case of LB. This is likely due to
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the greater inherent ability of LB to partition into octanol or SC lipids as compared to LH. From
all the above studies it is again evident that the predominant mechanism of drug permeation
enhancement is likely to be magnetokinesis. Additionally, the enhanced drug partitioning into the
lipid domain of the stratum corneum could be one of the potential mechanisms contributing,
which is more apparent in the case of the hydrophilic molecule than the lipophilic molecule.
6.4.6. Magnetophoretic transdermal patch system
One of the major tasks that need to be addressed when any physical permeation
enhancement technique is developed is its applicability in vivo. Techniques such as sonophoresis
and electroporation have been developed as device based techniques for short duration treatment
or pretreatment. The drug is delivered during the treatment or post treatment from a formulation.
Approaches such as iontophoresis and microneedles could be conveniently incorporated into a
transdermal patch system for prolonged drug delivery (169, 170). Magnetophoresis is a
phenomenon which occurs only in presence of the magnetic field or it is rather an induced effect.
Therefore it is more appropriate to incorporate this mechanism in the transdermal patch system
intended for prolonged application. As a continuation of the transdermal magnetophoresis
project, a simple transdermal patch system incorporated with magnetic field as the backing layer
was designed for in vivo drug delivery applications. A patch system with better aesthetic
appearance and workability could be made by improving the proposed system. LH and LB gels
were prepared using HPMC (4% w/v) for use as a drug reservoir in the patch system. The
backing membrane consists of a sequence of magnets arranged in parallel. The control patch was
developed by using similar nonmagnetic metal pieces in the backing layer. The design of patch
system is shown in Figure 6-4.
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A
B

a

b

Figure 6-4. Photographs of magnetophoretic patch system used for in vivo studies. In Figure a,
the magnetic backing could be clearly seen as it is not filled with the gel. In Figure b, the gel is
filled in the cavity ‘B’ (1.5 cm length, 1 cm width and 0.1 cm thickness) above the magnets. ‘A’
is the adhesive membrane to secure the patch onto the skin.

6.4.7. Transdermal drug delivery in vivo in rats
In vivo studies were carried out in rats whereas porcine epidermis was used for all the in
vitro studies. Though in vitro and in vivo data cannot be correlated due to the use of different
skin models, the in vivo data with rat model would supplement the findings from in vitro studies
and thus demonstrate the workability of the technique. Cutaneous microdialysis was employed as
a tool to investigate the time course of drug concentration in the skin. The in vivo microdialysis
probe recovery was found to 28.3±5.2 and 12.9±3.8% for LH and LB respectively. The patch
systems were applied on the abdomen region of rats. The time course of drug in the skin
extracellular fluid upon application of control and magnetophoretic transdermal patch systems is
shown in Figure 6-5 and 6-6 for LH and LB respectively.
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Figure 6-5. Time course of LH in the skin extracellular fluid following application of passive
transdermal patch (■) and magnetophoretic transdermal patch (●) in rats.

The area under the curve (AUC0-6h) which represents the dermal bioavailability and the
maximum concentration (Cmax) for both the salt and base forms of drug are given in Table 6-3.
LB being more lipophilic tends to permeate in higher amounts into the skin compared to LH.
Moreover, the use of ethanol for incorporating the lipophilic LB in the aqueous gel systems
might have also lead to enhanced passive drug permeation. The AUC0-6h was ~2-3-fold higher in
case of magnetophoretic patch system as compared to nonmagnetic control patch system (Table
6-3).
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Figure 6-6. Time course of LB in the skin extracellular fluid following application of passive
transdermal patch (■) and magnetophoretic transdermal patch (●) in rats.

Table 6-3. AUC0-6h and Cmax of LH and LB in the skin extracellular fluid following transdermal
application of passive and magnetophoretic patch systems in vivo in rats.

LH

LB

Parameter
Passive
patch

Magnetophoretic
patch

Passive
patch

Magnetophoretic
Patch

AUC0-6h
(µg.h/ml)

10.57 ± 2.05

23.02 ± 2.96

25.21 ± 4.05

53.96 ± 2.63

Cmax (µg/ml)

2.03 ± 0.26

4.56 ± 0.16

4.87 ± 0.48

10.39 ± 0.72
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6.5. CONCLUSIONS
Transdermal magnetophoresis is a phenomenon of the application of magnetic field to
enhance the drug delivery across the skin. This study demonstrates that the magnetic field could
be utilized to enhance the drug delivery across the skin. The magnetic field is believed to be a
relatively safer technique for use on skin as it was found to have no effect on the skin structure at
the field strengths utilized in this project. The in vivo studies demonstrated the feasibility of
developing a magnetophoretic transdermal patch system. The magnetophoretic patch systems
deliver drugs at a higher rate than the nonmagnetophoretic patch systems.
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CHAPTER-7
MAGNETOPHORESIS IN COMBINATION WITH CHEMICAL ENHANCERS FOR
TRANSDERMAL DRUG DELIVERY

7.1. ABSTRACT
The objective of the present project was to investigate the effect of combination of
magnetophoresis, a novel physical permeation enhancement technique and chemical permeation
enhancers on the transdermal delivery of drugs. The in vitro drug permeation studies were
carried out across freshly excised abdominal skin of Sprague-Dawley rats using transdermal
patch systems (magnetophoretic and non-magnetophoretic) of lidocaine hydrochloride.
Lidocaine hydrochloride gel prepared using HPMC was spread over the magnets as a thin layer.
To investigate the effect of chemical permeation enhancers, menthol, DMSO, SLS and urea (5%
w/v) were incorporated in the gels prior to loading on the patch system. The amount of drug
permeated across the skin was estimated by withdrawing samples from receiver compartment at
different time points. The permeation flux of lidocaine from magnetophoretic patch was about 3fold higher (3.07±0.6 µg/cm2/h) than that of the control (non magnetic patch) (0.94±0.3
µg/cm2/h). Incorporation of chemical permeation enhancers in the gel enhanced the
magnetophoretic permeation flux by ~5-7-fold. The enhancement factor due to combination of
chemical permeation enhancer and magnetic field was found to be additive of the individual
effects. From the mechanistic studies, magnetic systems were found to enhance the drug
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permeation via follicular pathway whereas the chemical enhancers increase the permeability of
bulk of the epidermis.
Keywords: Transdermal patch system, Follicular pathway, Chemical permeation enhancers,
Magnetophoresis.
7.2. OBJECTIVES AND SIGNIFICANCE
The objectives of the study are:
I.

To investigate the effect of chemical permeation enhancers on the magnetophoretically
mediated transdermal drug delivery.

II.

To investigate the potential mechanisms contributing to the drug delivery enhancement
across skin, when chemical enhancers and magnetophoresis are used in combination.

Various chemical enhancers and physical permeation enhancement techniques have been
investigated for overcoming the stratum corneum barrier and enhancing the transdermal delivery
of drugs (171-173). In general, physical permeation enhancement techniques are more efficient
than chemical enhancers. Several research groups have studied the effect of combination of
chemical enhancers and physical permeation enhancement techniques like iontophoresis,
electroporation and ultrasound to assess the plausibility of deriving synergistic benefits. Use of a
combination of enhancers is reported to mutually enhance the efficacy and also increase the
safety of enhancers. Oh et al. have reported that the transdermal transport of zidovudine was
enhanced synergistically when iontophoresis was used in combination with chemical enhancers
like propylene glycol and oleic acid (174). Ganga et al. showed that the combination of azone
and iontophoresis enhanced transdermal permeation of metoprolol synergistically (175).
Combination of ultrasound and sodium lauryl sulfate was reported to result in synergistic
enhancement in permeation of mannitol by Mitragotri et al. (176). Magnetophoresis is a
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phenomenon of enhancing drug permeation across the biological barriers by application of
magnetic field. Previous work by Murthy et al. has shown that magnetophoresis leads to
enhanced transdermal drug delivery in in vitro and in vivo studies (177). The predominant
mechanism for drug permeation enhancement was found to be magnetokinesis and enhanced
partitioning of drug into stratum corneum. In this study, the experimental data regarding
permeation enhancement of lidocaine hydrochloride using chemical enhancers and magnetic
field will be provided first followed by mechanistic studies (157, 178).
7.3. MATERIALS AND METHODS
7.3.1. Materials
Lidocaine Hydrochloride (LH) was obtained from Spectrum Chemicals (New Brunswick,
NJ), Estradiol, Ferric pyrophosphate, Menthol, Dimethyl sulfoxide (DMSO) and Sodium lauryl
sulfate (SLS) were purchased from Sigma-Aldrich Inc (St. Louis, MO). PBS 10x liquid
concentrate and Urea were procured from EMD Chemicals Inc (Cincinnati, OH) and all other
chemicals and reagents were obtained from Fischer Scientific (Fairway, NJ). Neodymium
magnets were purchased from K&J Magnetics Inc (Jamison, PA).
7.3.2. Drug transport from transdermal patch systems
The in vitro transport of lidocaine hydrochloride from transdermal patch systems across
the freshly excised rat abdominal skin was studied using vertical Franz diffusion cells
(diffusional area of 0.64 cm2 and receiver compartment volume of 5 ml). The barrier integrity of
rat skin was confirmed by measuring the electrical resistance according to previously published
methods and pieces of skin which had a resistance greater than 20 kΩ.cm2 were only used for the
drug permeation studies
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The design of transdermal patch system was similar to that described in section 6.3.12 and
Figure 6-4. Lidocaine hydrochloride (2% w/w) containing gel was prepared in HPMC base (4%
w/v) using deionized water and was spread over the magnets as a thin layer, which acts as drug
reservoir. DMSO, urea and SLS were incorporated in the gels prepared in deionized water
whereas menthol was incorporated in gel prepared in hydroalcoholic solution (water:alcohol,
70:30). The receiver compartment of diffusion cell was filled with PBS and drug permeation
studies were carried out by placing gel filled transdermal patches over the skin with samples
withdrawn at regular intervals of time over a period of 8 h.
7.3.3. Drug permeation studies across sandwich epidermis model
The mechanistic studies were carried out across the sandwich epidermis model prepared
from porcine epidermis. Sandwich epidermis model includes a layer of stratum corneum sample
placed over porcine epidermis. Stratum corneum samples are prepared from porcine epidermis
floated overnight on a aqueous solution containing 0.0001% w/v of trypsin and 0.5% w/v sodium
bicarbonate at 37 ○C according to method followed by Essa et al. and El Maghraby et al. (157,
178).
Passive and iontophoretic delivery of lidocaine hydrochloride, estradiol, and ferric
pyrophosphate were carried across sandwich epidermis and single layer epidermis and the steady
state flux was calculated. In case of lidocaine hydrochloride transport studies, the receiver
compartment of diffusion cell was filled with 5 ml of PBS, pH 7.4 and donor compartment was
filled with 0.5 ml of lidocaine hydrochloride (10 mg/ml) in PBS, pH 7.4. In case of estradiol
transport studies, the receiver compartment was filled with 5 ml of PBS, pH 7.4 containing 10%
HPßCD and the donor compartment was filled with 0.5 ml of estradiol (0.25 mg/ml) in PBS, pH
7.4 containing 40% alcohol. In case of ferric pyrophosphate transport studies, the receiver
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compartment was filled with 5 ml of PBS, pH 5 and the donor compartment was filled with 0.5
ml of ferric pyrophosphate (50 mg/ml) in PBS, pH 5. Anodal iontophoresis was carried out for
lidocaine hydrochloride and estradiol, whereas cathodal iontophoresis was used for ferric
pyrophosphate. In all the cases, 0.3 mA/cm2 of electric current was applied using an Iomed
Phoresor.
7.3.4. Analytical method
The amount of lidocaine hydrochloride, estradiol were analyzed by high performance
liquid chromatography and ferric pyrophosphate was analyzed by UV spectrophotometer. The
HPLC system (Waters, MA) consisted of a chromatographic pump (Waters 1525), autosampler
(Waters 717 plus) and an UV absorbance detector (Waters 2487). Symmetry® C18 column (4.6 x
150 mm) was used for analysis of lidocaine hydrochloride and the mobile phase consisted of a
mixture (14/86 v/v) of acetonitrile and potassium dihydrogen phosphate 0.05 M (pH adjusted to
4.0) with a flow rate of 1.3 ml/min at 216 nm (158). Phenomenox® Luna C18 column (4.6 x 150
mm) was used for analysis of estradiol and the mobile phase consisted of mixture of acetonitrile
and 0.1% ortho-phosphoric acid (6:4) with a flow rate of 1 ml/min at 212 nm (179). Ferric
pyrophosphate samples were analyzed at 510 nm using UV spectrophotometer after the addition
of Ferrover® reagent (180).
7.3.5. Statistical analysis
Statistical analysis was carried out using GraphPad InStat 3 software. Unpaired t-test was
performed and P<0.05 was considered as the level of significance. All the data are represented as
average of 3-5 trials with standard deviation.
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7.4. RESULTS AND DISCUSSION
7.4.1. Development of transdermal patch system incorporated with chemical enhancer and
magnetic backing
The magnetophoretic patch system consists of magnets arranged in parallel on the
adhesive backing membrane. A row of magnetic blocks were used instead of a single magnet
mainly to impart flexibility to the patch system. Magnets in the backing membrane were replaced
with nonmagnetic pieces in case of non-magnetophoretic patches. The patches containing
nonmagnetic backing were used to study the effect of chemical permeation enhancers on the
delivery of drug from the patch system. The drug along with chemical enhancers incorporated in
the gel was filled into the cavity of adhesive backing membrane. About 200 mg of gel was
loaded onto the patch system which contained lidocaine hydrochloride equivalent to 2 mg.
Different chemical enhancers were incorporated into the gel to enhance the drug permeation
across the skin. DMSO is known to be an effective permeation enhancer for both hydrophilic and
lipophilic drugs. On application to skin, DMSO is known to denature the proteins and change the
confirmation of intercellular keratin from α helical to ß sheet and also interacts with the
intercellular lipid regions of the stratum corneum (181-183). Terpenes have been reported to be
safe and effective permeation enhancers for both hydrophilic and lipophilic drugs (184). Menthol
has been studied as permeation enhancer for hydrophilic drugs like 5-fluorouracil and
propranolol hydrochloride (185, 186). The main reason for enhancement of permeation of
hydrophilic drugs by menthol is due to the disruption of the stratum corneum lipids by breakage
of hydrogen bonds between the ceramide groups (187). Urea has been known to act as a skin
permeation enhancer by increasing the stratum corneum water content and thus leading to
opening of hydrophilic diffusion channels within the stratum corneum. SLS is known to
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solubilize the stratum corneum lipids and also interact with keratin to enhance the overall skin
permeability (39, 149).
7.4.2. Magnetophoresis mediated drug delivery enhancement
The passive permeation flux of lidocaine hydrochloride across rat skin was found to be
0.94±0.13 µg/cm2/h. The permeation flux of lidocaine hydrochloride was enhanced by ~3-fold
(3.07±0.43 µg/cm2/h) in case of magnetophoretic patch system compared to that of passive.
7.4.3. Effect of chemical enhancers on the drug delivery from transdermal patch systems
Incorporation of chemical enhancers has resulted in an increase in the permeation flux of
lidocaine hydrochloride compared to control (gel without any chemical enhancer). The
concentration of all the four enhancers used in the present study was at 5% w/v. The drug
permeation enhancement factor of different enhancers could be represented in the following
decreasing rank order: menthol > SLS > urea > DMSO. Incorporation of menthol in the gel
formulation resulted in ~3.7-fold enhancement (3.50±0.69 µg/cm2/h) in the flux of lidocaine
hydrochloride. Due to limited solubility of menthol in the aqueous vehicle, 30% v/v of alcohol
was used in the gel formulation to incorporate menthol (the flux enhancement by 30% v/v
alcohol alone in absence of menthol was found to be ~1.4-fold over control). SLS resulted in
~2.6-fold enhancement (2.44±0.39 µg/cm2/h) in the permeation flux over the control patch. On
the other hand, urea and DMSO lead to ~1.7-fold (1.62±0.27 µg/cm2/h) and ~1.1-fold (1.07±0.24
µg/cm2/h) enhancement in the flux over the control patch. Among the enhancers, menthol and
SLS resulted in greater enhancement compared to urea and DMSO. Except DMSO, all the other
chemical enhancers showed a significant enhancement in the flux of lidocaine hydrochloride
(Figure 7-1).
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Figure 7-1. Transdermal permeation flux of lidocaine hydrochloride from non-magnetophoretic
patch systems. ‘Control’ indicates patch system without any chemical enhancer. ** indicates
statistically insignificant and * indicates statistically significant compared to control.

The effect of pretreatment was not considered because the effective pretreatment varies with
each chemical enhancer and would not clearly reflect the relative efficiency. Moreover, in real
life situation, the patch containing combination of chemical enhancers and magnetophoresis will
be applied by the patients. Therefore, the studies included simultaneous application of both the
enhancers (chemical enhancers and magnetophoresis) in the patch system to simulate the in vivo
practice.
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7.4.4. Effect of combination of chemical enhancers and magnetophoresis on the drug
delivery
Combination of chemical enhancers and magnetophoresis resulted in enhanced
permeation flux compared to both individual chemical enhancer effect and magnetophoretic
effect and was additive in most of the cases (Table 7-1). Definitely, there was a significant
increase in the enhancement efficiency with this combination approach. Moreover, the results
clearly demonstrated the feasibility of incorporating chemical permeation enhancers and
magnetophoresis technique in a simple transdermal patch system, which could be of potential
benefit in enhancing the transdermal delivery of poorly permeable drugs. The plausible reason
for an additive effect is likely due to the difference in the predominant mechanism of drug
delivery enhancement between the chemical enhancers and magnetophoresis. Among the
enhancers used, menthol and SLS are known to act predominantly on the lipoidal regions
whereas DMSO and urea act on the keratinocytes. Our earlier studies have shown that the
magnetically mediated transdermal drug delivery is more likely due to interaction of the
magnetic field with the drug molecule than with the stratum corneum barrier. In the mechanistic
studies sandwich epidermis model was used to elucidate the predominant mechanism of
enhancement of drug delivery by the application of magnetic field.
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Table 7-1. Transdermal permeation flux of lidocaine hydrochloride from non-magnetophoretic
and magnetophoretic patch system. ‘Control’ in the table indicates patch system without any
chemical enhancer. Enhancement factor is the ratio of permeation flux obtained with respect to
flux from control (non-magnetophoretic patch system).
Non-magnetophoretic patch
Enhancer

Magnetophoretic patch

Permeation flux
(µg/cm2/h)

Enhancement
Factor

Permeation flux
(µg/cm2/h)

Enhancement
Factor

Control

0.94 ± 0.13

1.00

3.07 ± 0.43

3.26

DMSO

1.07 ± 0.24

1.13

3.82 ± 0.48

4.06

Urea

1.62 ± 0.27

1.72

4.85 ± 0.24

5.15

SLS

2.44 ± 0.39

2.59

4.93 ± 0.37

5.24

Menthol

3.50 ± 0.69

3.72

6.06 ± 0.43

6.44

7.4.5. Mechanistic studies
In a recent report, the results of the mechanistic studies clearly demonstrated that
magnetokinesis was the predominant mechanism responsible for enhanced transdermal
permeation (177). However, the relative contribution of appendageal pathway in magnetokinesis
has not been investigated. Mechanistic studies were carried out using sandwich epidermis model
developed by El Maghraby et al. to elucidate the role of appendageal pathway in drug
permeation across the skin (178). In the sandwich epidermis model, the stratum corneum layer
overlaid on the epidermal membrane forms the top layer and blocks most of the appendageal
pathways present in underlying epidermal membrane (Figure 7-2).

99

Figure 7-2. Sandwich epidermis model. 2a represents single layer epidermis with unblocked
appendageal pathway and 2b represents sandwich epidermis with a stratum corneum layer
overlaid on the epidermal membrane. Appendageal pathway of underlying epidermal membrane
is blocked by the overlaid stratum corneum layer and appendageal pathway of the overlaid
stratum corneum layer is blocked by the underlying epidermal membrane. In case of sandwich
epidermis, the permeation flux of hydrophilic drugs which permeate mostly through appendageal
pathway would be reduced by less than half and be close to zero due to blockage of appendageal
pathway. However, the permeation flux of lipophilic drugs which permeate mostly through the
bulk of epidermis (non-appendageal pathway) would be reduced by half due to increase in
thickness of the barrier, in the case of sandwich epidermis.
In this study porcine epidermis was used to carry out mechanistic studies using sandwich model
due to ease of separation of epidermis when compared to rat skin. El Maghraby et al. have
carried out permeation studies across the sandwich epidermis and compared it with that across
the epidermis alone (178). The authors reported that the permeation through sandwich epidermis
model would be much reduced in comparison to epidermis if appendageal pathway played an
active role in the permeation of drug. It was reported that appendageal pathway played only a
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minor role in the penetration of liposomal formulations containing estradiol. Essa et al. used the
same model to examine the role of skin appendages in the passive, iontophoresis and liposomal
penetration of drugs and reported that the appendageal pathway played a major role in the
passive permeation of hydrophilic mannitol, where as it was negligible in case of lipophilic
estradiol (157). The authors also reported that the appendageal pathway had a significant role in
the flux enhancement by iontophoresis (157, 178).
Initially, a few set of experiments were dedicated to validate the sandwich epidermis model
reported by El Maghraby et al. Permeation studies were carried out using lidocaine
hydrochloride, estradiol and ferric pyrophosphate. Lidocaine hydrochloride is a cationic
hydrophilic drug and estradiol is lipophilic in nature. Ferric pyrophosphate represents a high
molecular weight anionic hydrophilic compound. Therefore, the three marker drugs differ in
their extent and pathways of transdermal permeation.
7.4.5.1. Passive permeation studies across sandwich epidermis and single layer epidermis
The passive permeation flux ratio of sandwich model to single layer epidermis (FSW/SL)
would be close to 0.5, if appendageal pathway had no role in drug permeation and the FSW/SL
would be <0.5 and close to zero if the drug permeation was via appendageal pathway. In general,
highly hydrophilic drugs permeate through skin mainly via appendageal pathway whereas
lipophilic drugs permeate mainly through the bulk of the skin (188, 189). Based on this one
would expect FSW/SL would be <0.5 for lidocaine hydrochloride and ferric pyrophosphate which
are hydrophilic and 0.5 for estradiol which is lipophilic in nature.
The steady state flux of lidocaine hydrochloride was found to be 1.45±0.02 µg/cm2/h across the
single layer porcine epidermis. The flux decreased significantly to 0.24±0.01 µg/cm2/h across the
sandwich epidermis (Figure 7-3). The FSW/SL was ~0.16 indicating that the appendageal pathway
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had a significant role in the passive permeation of lidocaine hydrochloride (Table 7-2). However,
the diffusion across the bulk of the epidermis is not completely negligible in this case. This is
likely because of the presence of unionized fraction of the drug, which tends to selectively
diffuse via bulk of the epidermis pathway.

Amount of lidocaine hydrochloride
permeated (µg/cm2)

15
12
9
6
3
0
0

2

4
Time (h)

6

8

Figure 7-3. Passive permeation of lidocaine hydrochloride across single layer (●) and sandwich
epidermis (■).

The passive permeation flux of estradiol was found to be 0.042±0.004 µg/cm2/h and 0.023±0.003
µg/cm2/h across single layer epidermis and sandwich epidermis respectively with FSW/SL of 0.54
(Figure 7-4, Table 7-2). The results indicate that the appendageal pathway did not play a
significant role in the permeation of lipophilic estradiol and hence the flux was reduced by
almost half across the sandwich epidermis. This was in agreement with the results reported by
Essa et al. for estradiol permeation across the human epidermis (157).
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Ferric pyrophosphate did not result in any passive permeation across the porcine epidermis
which could be due its high molecular size and extremely hydrophilic nature.

Amount of estradiol permeated
(µg/cm2)

2.4

1.8

1.2

0.6

0.0
0

12

24

36 48
Time (h)

60

72

Figure 7-4. Passive permeation of estradiol across single layer (●) and sandwich epidermis (■).
7.4.5.2. Iontophoretic drug delivery across sandwich and single layer epidermis
Anodal iontophoresis would favor the transdermal delivery of lidocaine hydrochloride
and at pH over 5, both electroosmosis and electrophoresis contribute to the enhanced transport of
drug. In case of estradiol, permeation could be enhanced only by electroosmosis mechanism due
to lack of any charge on the molecule (157). Ferric pyrophosphate was found to be poorly
permeable across the skin by passive diffusion and the permeation could be enhanced
significantly by cathodal iontophoresis at pH over 5. In case of ferric pyrophosphate, recent
studies by Murthy and Vaka have shown that electroosmosis does not play any role in the
enhanced permeation and the main pathway for enhanced permeation by iontophoresis is through
appendageal pathway (180). So, in the present study, anodal iontophoresis was carried out for
lidocaine hydrochloride and estradiol whereas cathodal iontophoresis was carried out for ferric
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pyrophosphate. The flux of lidocaine hydrochloride across sandwich epidermis decreased to
2.86±0.63 µg/cm2/h in comparison to 12.54±1.98 µg/cm2/h across single layer epidermis and
I

FSW/SL (ratio of iontophoretic flux across sandwich model to single layer epidermis) was found

to be 0.22 (Figure 7-5, Table 7-2). In case of estradiol IFSW/SL was found to be 0.19 with a flux of
0.022±0.002 µg/cm2/h across the sandwich epidermis model and 0.111±0.007 µg/cm2/h in case
of single layer epidermis (Figure 7-6, Table 7-2). Assuming complete blockade of appendageal
pathway, IFSW/SL should be close to zero. But permeation of both lidocaine and estradiol was
observed which might be due to the electroosmosis mediated transport of drug through the
additional pores created in the bulk of the skin by application of iontophoresis. These results are
in agreement with that reported by others (157, 178). Murthy and Vaka demonstrated that the
iontophoretic delivery of ferric pyrophosphate occurs only through appendageal pathway across
the rat skin (180). In this study using porcine epidermis, IFSW/SL of ferric pyrophosphate was only
0.04, with flux of 1.58±0.10 µg/cm2/h and 37.69±4.68 µg/cm2/h across sandwich and single layer
epidermis respectively (Figure 7-7, Table 7-2). These results of the validation studies confirm
that the appendageal pathway is almost completely blocked in the sandwich epidermis model and
it could serve as an excellent model to investigate the contribution of appendageal pathway in the
drug transport. Barry has also proposed that sandwich epidermis model can be applied
effectively to analyze appendageal pathway in case of ultrasound and magnetophoresis studies in
addition to passive diffusion and electrical methods (190). Therefore, the sandwich epidermis
model was used in case of magnetophoresis mediated studies to elucidate the mechanism of
appendageal pathway.
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Amount of lidocaine hydrochloride
delivered (µg/cm2)

90
75
60
45
30
15
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Time (h)
Figure 7-5. Iontophoretic delivery of lidocaine hydrochloride across single layer (●) and
sandwich epidermis (■).

Amount of estradiol delivered
(µg/cm2)
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Figure 7-6. Iontophoretic delivery of estradiol across single layer (●) and sandwich epidermis
(■).
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Amount of ferric pyrophosphate
deelivered (µg/cm2)
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Figure 7-7. Iontophoretic delivery of ferric pyrophosphate across single layer (●) and sandwich
epidermis (■).
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Table 7-2. Steady state flux of lidocaine hydrochloride, estradiol, and ferric pyrophosphate
following passive permeation and iontophoretic delivery across sandwich and single layer
epidermis with corresponding flux ratios.
Flux (µg/cm2/h)
Drug

Sandwich
epidermis

Single layer
epidermis

Flux ratio
(sandwich
/single
layer)

Role of
appendageal
pathway

Passive permeation
Lidocaine
Hydrochloride

0.24 ± 0.01

1.45 ± 0.02

0.16

Significant

Estradiol

0.023 ± 0.003

0.042 ± 0.004

0.54

Insignificant

Ferric
pyrophosphate

-

-

-

-

Iontophoretic delivery
Lidocaine
2.86 ± 0.63
12.54 ± 1.98
0.22
Significant
Hydrochloride a
Estradiol b
0.022 ± 0.002 0.111 ± 0.007
0.19
Significant
Ferric
1.58 ± 0.10
37.69 ± 4.68
0.04
Significant
pyrophosphate c
a
b
Anodal iontophoresis
Anodal iontophoresis cCathodal iontophoresis
The potential mechanisms are electroosmosis and electrorepulsion in case of b and c
respectively. In case of a both electrorepulsion and electroosmosis contribute together.
7.4.5.3. Magnetophoretic delivery of lidocaine hydrochloride across sandwich and single
layer epidermis
These studies were carried out to determine the extent of contribution of appendageal
pathway in magnetically enhanced drug permeation. Drug permeation studies were carried out
across porcine epidermis using transdermal patch system. The flux of lidocaine hydrochloride
from magnetophoretic patch system across single layer epidermis and sandwich epidermis was
found to be 3.87±0.30 µg/cm2/h and 0.99±0.26 µg/cm2/h respectively. The

M

FSW/SL (ratio of

magnetophoresis flux across the sandwich model to single layer epidermis) would have been
close to 0.5 if appendageal pathway had no significant role in the drug permeation by
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magnetophoresis. But, MFSW/SL was found to be 0.25 indicating that appendageal pathway played
a significant role in the magnetophoretic delivery of lidocaine hydrochloride.
From the mechanistic studies reported earlier and in the present paper, it is more evident that the
magnetic field enhances the drug delivery across the skin predominantly by magnetokinesis
across the appendageal pathway without significantly affecting the stratum corneum barrier. In
addition, the present study indicates that the use of chemical permeation enhancers which
interact with the bulk of the epidermis (non appendageal region) would improve the overall drug
delivery efficiency.
7.5. CONCLUSIONS
The results indicate that the magnetically mediated drug permeation enhancement could
be further enhanced by incorporation of suitable chemical permeation enhancers. The magnetic
systems were found to enhance the drug permeation via appendageal pathway.
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